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   In the past 15-20 years, advances in antibody engineering have 
facilitated the generation and isolation of monoclonal antibodies (mAbs) to a wide array 
of antigens. Consequently, mAbs have become essential therapeutic tools and currently 
dominate the global protein therapeutics market. The engineering of anti-infective 
antibodies, however, has proven quite a challenge, despite the fact that antibodies were 
naturally evolved to fight infections. The identification of suitable antigens, the mode of 
administration and the high cost associated with the production of antibody therapeutics 
are some of the major hurdles for the progress of anti-infective antibodies. This 
dissertation addresses issues concerning the development of anti-infective antibodies 
against two different pathogens: SARS coronavirus (CoV) and two pathogenic species of 
Burkholderia bacteria.  
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   To investigate the role of affinity in viral neutralization and evolution of escape 
mutants, we first sought to isolate an antibody with high affinity towards the receptor 
binding domain (RBD) of SARS-CoV. Following high-throughput screening of a library 
of random mutants via the APEx display system, we isolated antibodies with affinities in 
the range of 0.8 nM - 0.1 nM. The affinity was further improved by additional 
mutagenesis and DNA shuffling, and a high affinity variant (45pM) with ~300-fold 
improvement over the parental antibody was isolated. Evaluation of these antibodies in 
an in vitro assay demonstrated that neutralization of wild-type Urbani strain of SARS-
CoV correlates well with the affinity of the antibody, with higher affinity leading to 
greater neutralization. Moreover, the antibody exhibiting the highest affinity could 
neutralize SARS-CoV escape mutants that evaded neutralization by both parental and 
lower affinity antibodies. 
   Another important aspect for the development of anti-infective antibodies 
concerns the identification of suitable antigen targets to be used in the isolation of 
antibodies. In an effort to develop a high-throughput screening method for the isolation of 
antibodies to a wide array of antigens, we used a synthetic antibody (Fab) library 
constructed by a minimalist approach and displayed on the surface of filamentous 
bacteriophage. The library was screened against antigens from Burkholderia 
pseudomallei and Burkholderia mallei. After only three rounds of selection and 
enrichment against five different antigens, we obtained Fabs specific to four of the 
antigens as confirmed by ELISA. These results not only demonstrate the use of a 
synthetic antibody library for the isolation of antibodies against infectious pathogens, but 
 vii 
also its feasibility, and potential applicability as a high-throughput screen for a variety of 
antigens.  
 viii 
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   The human immune system plays a crucial role in protecting the human body 
against infectious diseases. The human body faces a constant onslaught of pathogens 
from the environment, and as a primary physical barrier, the skin and mucosal 
membranes prevent the entry of these microbial pathogens into our body. When 
pathogens cross these formidable barriers, the immune system is activated. The immune 
system is made up of a complex network of cells, tissues and organs that help the body 
fight infections by identifying and destroying pathogens. The immune system responds in 
2 ways: a nonspecific innate immune response and a specific adaptive immune response. 
 As a first line of defense, the innate immune responses provide a rapid and non-
specific response to microbial challenges. Pathogens are recognized by innate immune 
cells including macrophages and neutrophils, which help in controlling common 
infections.  However, the innate immune response has a key limitation in that, by itself, it 
cannot eliminate pathogens once an infection has been established. It is the adaptive 
immunity activated by the innate immune system that provides a more versatile means of 
defense against such pathogens. Adaptive immunity also protects against re-infection 
through immunological memory. The adaptive immune response is highly specific and 
responds with great precision against specific antigens. The adaptive immune response is 
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further divided into humoral immunity (B-cell response) and cell mediated immunity (T-
cell response)(24, 124).  
   Antibodies are the key elements of the adaptive immune system, and play a 
critical role in defense against a wide array of antigens presented by invading microbial 
pathogens. Being part of humoral immunity, they provide protection through the binding 
of pathogens (neutralization), promoting phagocytosis by opsonization, and by activation 
of complement. These elaborate defense mechanisms do fail against certain pathogens, 
leading to some well-known pandemics (24, 107).  
  The significance of antibodies in controlling infections has been known for over a 
century, when serum therapy was used to treat infectious diseases. Serum therapy lost 
favor with time due to adverse reactions associated with it and the easy access to 
antibiotics. The development of the hybridoma technology revolutionized antibody 
therapy by providing an efficient means to generate monoclonal antibodies. With the 
greater understanding of the structure and function of antibodies, along with the major 
developments in recombinant DNA technology and protein engineering, it is now 
possible to modify and fine tune the properties of antibodies for specific applications(23).  
  Currently, antibodies are a rapidly growing class of biomolecular therapeutics 
second only to vaccines, with 23 FDA approved antibodies in the market (Table 1.1). 
About 200 different antibody based therapeutics are in the clinical trials targeting about 
70 different molecules (33). In 2008, total sales of antibodies reached nearly $32 B and 
has grown rapidly to represent over 30% of the global biologic drug market (171) and is 
estimated to surpass 50% by 2010.  The major driving force for antibody therapeutics in 
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the future will be improvement in the properties of existing antibodies, identification of 
novel antibodies, novel targets, and use of novel scaffolds.   
  This chapter presents an overview of the structure and functions of antibodies, 
and will give an outline of the current and developing technologies in the antibody 
engineering field. 

















Table 1.1: FDA approved monoclonal antibodies (Current as of May 2009)(133) 
2008Crohn’s disease0.089Humanized fabCertolizumab Pegol
2003Allergy related asthma 0.17Humanized IgG1Omalizumab
2006Macular degeneration0.14Humanized IgG1 FabRanibizumab
2002Non Hodgkin’s Lymphoma14-18
Mouse IgG1, 90Y 
labeled
Ibritumomab tiuxetan


















YearApproved TreatmentKd (nM)Antibody FormatAntibody










  Antibodies are antigen-recognition gamma globulin proteins (immunoglobulins) 
secreted by plasma B cells (differentiated B cells) that are employed by the immune 
system to recognize and neutralize pathogens. The antibody molecule is made up of four 
polypeptide chains - two identical H-heavy (50kDa) and two identical L-light chains 
(25kDa), with heavy (H) and light (L) chain being covalently linked through disulfide 
bonds.  The immunoglobulins are differentiated into five classes, defined by the structure 
of the heavy chain. They are IgM, IgD, IgG, IgA and IgE, and their heavy chains are 
denoted as µ, δ, γ, α & ε respectively. IgG is the most abundant immunoglobulin isotype 
in the plasma. The major differences among these classes are in the hinge and Fc 
(Fragment crystallizable) regions, which lead to differences in their effector function and 
in the polymerization state. There are only two types of light chains- kappa (κ) and 
lambda (λ), and there is no known functional difference between the two (24). 
  The antibody molecule is divided into two functional regions, the antigen binding 
region and the Fc region.  The antigen binding region varies widely between antibody 
molecules and is composed of the variable domain (V domain), and constant domain (C 
domain).  The actual antigen binding site is formed by the amino terminal V domain of 
both the heavy and light chains (VH and VL).  The fully folded antibody molecule is 
comprised of three globular domains linked by a flexible polypeptide chain known as the 
hinge region to form a Y shaped structure.  Papain cleaves the immunoglobulin into two 
identical antigen binding fragments (Fab – 50KDa) and a crystallizable fragment (Fc- 
50KDa). Each domain has the characteristic immunoglobulin fold consisting of two anti-
parallel sheets with intra-molecular disulfide bonds. Disulfide bonds are an important 
 5 
component of IgG structure, in that intra-chain disulphide bonds stabilize each domain, 
and interchain disulfide bonds reinforce association of H and L chains (antigen binding 
region) as well as H chains (Fc region) (136) (Fig 1.1).  








Figure 1.1:  a. Crystal structure of an antibody - light chains are in green and pink, 
heavy chains in light blue and dark blue, disulfide bonds in yellow space fill and 
carbohydrates in white wireframe. 
b. Schematic representation of an antibody 
 
Antigen recognition: 
  The recognition of antigen is mediated by the contributions of both heavy (VH) 
and light (VL) chains.  Each variable region has three sections of high amino acid 
sequence divergence or variability, termed hypervariable regions, which are separated by 
conserved framework regions (FR). The areas of the antibody binding site that contact the 
antigen as determined by crystallographic studies are referred to as complementary 
determining regions (CDRs) and the CDRs correspond to the hypervariable regions 






















β strands, with the six CDRs forming loops at the ends of these strands to create the 
antigen binding site.  
Antibody binding depends on the size and shape of the antigen.  Smaller antigens 
such as haptens, small peptides or carbohydrates generally bind in a groove formed at the 
interface of the heavy and light chain CDR’s.  Larger protein molecules generally involve 
larger contact surface areas, which sometime extend into the frameworks. (24).  
The antibody recognition site on the antigen is known as the antigenic 
determinant or epitope.   These sites are often discontinuous, meaning the antibody binds 
to residues that are adjacent to each other on the protein surface, yet are not next to each 
other in primary sequence (169).  The interaction between an antigen and antibody is 
reversible, being held together through non-covalent interactions including electrostatic 
forces, van der Waals forces, hydrophobic forces, and hydrogen bonds.  
Effector functions of antibodies: 
  One of the most simple and direct ways antibodies provide immunological 
protection is through binding to receptor sites on pathogens or released toxins, thereby 
blocking pathogenic activity. This process is referred to as neutralization. However, 
neutralization alone does not always provide complete protection as it can fail to hinder 
pathogen replication. In addition to neutralization, antibodies also contribute to immunity 
via a process referred to as opsonization as well as through the activation of the 
complement system, both of which rely on Fc region of the antibody. To combat 
pathogens that replicate outside cells, antibodies coat the pathogen and stimulate effector 
functions against the pathogen via cells that recognize antibody Fc regions. This coating 
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of pathogens by antibodies and the resulting attack by the immune system is known as 
opsonization. The cells with Fc receptors that recognize these coated pathogens lead the 
destruction of the pathogen through phagocytosis or release of cytotoxins (Fig 1.2)(107).  
      
Figure 1.2: Effector functions mediated by antibody Fc. Adapted with permission 
from Nature Biotechnology (107) 
  
  The complement system is a biochemical cascade of more than 20 different 
proteins that “complements” the function of antibody. The activated complement 
components can either directly kill bacteria by forming pores in the cell wall, or through 
opsonization.  Since the Fc receptors are isotype-specific, the immune system has greater 




  Antibody therapy began a century ago with the discovery that serum from 
immunized animals can be effective against the disease caused by the same agent in 
humans. The discovery and development of serum therapy for Diphtheria brought the 
first Nobel Prize in Medicine to Von Behring in 1901. However, with the intensified 
competition from widely available antibiotics, serum therapy was abandoned due to 
problems related to the toxicity and high incidence of allergic reactions.  One of the 
major breakthroughs in the field was the development of the hybridoma technology in 
1975, which provided the means to generate large amounts of monoclonal antibodies 
(23). Moreover, with the advent of recombinant DNA technology, it has been possible to 
engineer the size, immunogenicity, binding affinity, specificity, pharmacokinetics and 
effector functions of antibodies (160). Because of antibody engineering, antibody based 
therapeutics currently enjoy remarkable commercial success. It appears that Paul 
Ehrlich’s concept of “magic bullets” has largely been realized, though it took more than 
100 yrs to attain the goal. This introduction provides an update of the field along with the 
latest technologies that has been radically transforming the field in the last two decades. 
Antibody cloning: 
  The hybridoma technology which was developed in 1975 and relies on the 
production of antibodies from cell lines formed by the fusion of B-cells from an 
immunized animal with myeloma cells, still remains as one of the core technologies and 
established the field of antibody engineering. In the late 1980s, with the help of the 
recombinant DNA technology, cloning and expression of antibodies in different model 
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systems became possible with polymerase chain reaction (PCR) simplifying the process 
of cloning antibody genes.  Diverse expression systems including bacteria, yeast, 
filamentous fungi, insect, plant, or mammalian cells and transgenic animals have been 
used for the expression of recombinant antibodies. Choice of expression systems usually 
depends on the form of antibody expressed, but in many cases several different 
expression systems can be used. Eukaryotic systems are preferred for the expression of 
full length IgGs since they have the cellular machinery for efficient folding and assembly 
and also allow glycosylation, which is important for therapeutic purposes(17). Antibody 
fragments have a simpler structure and do not require glycosylation hence they can be 
efficiently expressed in bacterial systems.  
       Antibodies are cloned from mRNA isolated from hybridoma cells, spleen or 
lymph cells, which are reverse transcribed into DNA and then the antibody genes are 
amplified by PCR.  To amplify the variable domain genes by PCR, degenerate primers 
are used, comprised of a 3′ set complementary to the constant region sequences and a 5′ 
set that are complementary to variable region sequences. Most commonly used primers 
are based on framework region amino acid sequences from Kabat and V-base databases.  
IgG is the most abundant immunoglobulin in blood as well as the most commonly used 
form for antibody therapeutics(24). Heterologous expression in E. coli has made it 
possible to construct a wide variety of functional antibody fragments such as the antigen 
binding domain (Fab), single-chain Fv (scFv) comprised of the antigen binding site VH 
&VL joined by flexible linker, single domain antibodies (dAb),the smallest functional 
binding unit corresponding to either VH or VL alone, and engineering of multivalent 
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oligomers like diabodies, triabodies or tetrabodies to enhance the functional affinity 
through avidity (90) (Fig 1.3).         
              
 
 
Figure 1.3: Schematic representation of different antibody formats.  
 
Immunogenicity: 
   In order to be therapeutically effective, antibodies must exhibit high specificity 
and affinity with minimal immunogenicity. In general, murine mAbs cannot be used as 
therapeutic agents because of their immunogenicity in humans. Antibody engineering has 
been used successfully to overcome immunogenicity through a process known as 










































murine CDRs are grafted into human framework scaffold (137). Unfortunately, this 
method usually lowers the affinity of the humanized antibody (44).  In another approach 
known as resurfacing, only surface residues predicted to be immunogenic are replaced 
with the corresponding human amino acid (139). More recently, selective humanization 
strategies that utilize screening of libraries by phage display have been reported (80). 
   Other than primary amino acid sequence, the presence of misfolded antibody 
molecules, contaminants, heterogeneity of antibody pool (glycosylation, deamidation), 
and presence of T cell epitopes can contribute towards immunogenicity of a therapeutic 
antibody formulation. Clinical parameters like dose, route, frequency of administration, 
including disease and immune status of patients can also influence the immunogenicity of 
antibodies(22). 
Antibody Libraries: 
  The progress in antibody engineering generated the necessity of constructing 
highly diverse libraries to screen for antibodies with high antigen specificity and affinity. 
Generally, three types of libraries are used (1); immune, naïve or synthetic.  Immune 
libraries are obtained from either B cells of immunized animals or human immune B cells 
and are the best source for the isolation of high affinity antibodies.  These libraries take 
advantage of the in vivo affinity maturation process in the donor and are usually 
comprised of <108 clones.  Significant limitations of immune libraries include a lack of 
an immune responses to some antigens, and as well as the unsuitability of some antigens 
for immunizations. Naïve libraries are isolated from B-cells of non-immune animals or 
humans.  The absence of in vivo affinity maturation necessitates the construction of a 
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large library to increase the odds of finding antibodies specific for a given antigen of 
interest.  It is worth pointing out that the cloning process from isolated B cells involves 
amplifying the heavy and light chain genes independently, meaning that heavy-light 
chain pairing information is lost, leading to an unintentional chain shuffling during 
library construction.  This is presumably the reason that antibodies to self-antigens have 
been isolated from these libraries (8, 39).   
Synthetic and semi-synthetic libraries provide an alternative to the reliance on 
repertoires from animals or humans, and can overcome the problem of diversity and 
immunological tolerance. Such  combinatorial libraries constructed with more than 1011 
different antibodies of distinct antigen specificities  in a small volume can be assumed as 
an incarnation of a test tube full of Ehrlich’s “magic bullets” (97). These libraries are 
assembled from synthetic oligonucleotides that introduce complete or partial sequence 
degeneracy mainly into CDR loops, resulting in an overall diversity that bypasses natural 
biases and redundancies.  The first generation of semi-synthetic libraries used a repertoire 
of VH and VL genes from human germline with synthetic CDR3 with varying CDR3 
lengths (32, 120), as CDR3 plays a dominant role in antigen recognition. The second 
generation of libraries relied more on expression and stability of the frameworks, by 
using a limited set of variable domain scaffolds (4, 81, 130). One of the most 
comprehensive libraries yet reported, the so-called “HuCal” library, is a fully synthetic 
library with about 2x109 clones. It was constructed from seven VH and seven VL 
germline families that covered >95% the presumed human antibody diversity, and was 
optimized for expression in E.coli (88). In a completely different approach, Sidhu and his 
colleagues have used a minimalistic approach to construct a synthetic library based on the 
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bias of natural CDR sequences in favor of tyrosine and serine. They constructed a 
synthetic library with CDR diversity restricted to only four amino acids (Tyrosine, 
Serine, Alanine and Aspartate), and were successful in isolating high affinity antibodies 
against VEGF (147). They further simplified the diversity to a binary combination of 
tyrosine and serines resulting in a highly functional library (42) and introduced additional 
diversity into CDR3 to enhance the diversity and functionality of the library. 
 
LIBRARY SCREENING TECHNOLOGIES: 
  Successful isolation of antibodies from large combinatorial libraries that exhibit 
high specificity towards an antigen of interest relies heavily on the screening technology 
employed.  Because of the large sizes of many antibody libraries (106-1011), a variety of 
efficient high-throughput technologies has been developed. There are three major 
screening methods currently in use, namely phage display, cellular display and in vitro 
display systems.  Not surprisingly, it has been demonstrated that different antibodies are 
isolated from the same library using different screening methodologies, so choosing a 
suitable method to screen an antibody library is a critical consideration(66).  
A common thread that links the various antibody library screening platforms is 
the requirement for a physical linkage between genotype (encoding DNA) and phenotype 
(binding activity), thereby allowing a simultaneous isolation of the genes that encode an 
antibody of interest based on its binding function. This not only allows the enrichment of 
desired antibodies via application of selection pressure, but also amplification after 
selection (Fig 1.4)(8).  
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Figure 1.4: Schematic representation of selection and screening of antibodies from 
the libraries. Adapted with permission from Nature Biotechnology (66) 
Phage display: 
  Antibody phage display is one of the most popular and extensively used selection 
platforms, and was first reported by McCafferty et al in 1990 (114).  The display on a 
filamentous bacteriophage surface is achieved by the fusion of an antibody fragment to a 
coat protein of the phage particle, such as pIII or pVIII of M13. M13 is the most 
frequently used filamentous bacteriophage and the pIII coat protein is usually preferred 
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for display. The display of antibody fragments on a phage particle can either be 
monovalent or polyvalent(20). Monovalent display is achieved by cloning the antibody 
fragment gene in frame with the pIII gene in a phagemid vector. Phagemids are plasmid 
vectors that lack the genes required for packaging into virions. However, subsequent 
infection of bacteria carrying phagemid vectors with helper phage provides the necessary 
genes for replication and packaging of phagemid into virions (Fig 1.5). The wild type 
pIII, encoded by the helper phage, competes with the antibody-pIII fusion encoded by the 
phagemid, resulting in lower levels of fusion display, often monovalent (20). The 
advantage of monovalent display is the efficient selection of high affinity antibodies 
because of the absence of the avidity effect (6, 121). Polyvalent display is achieved by 
cloning in frame with the pIII of the phage genome, which then displays antibody on all 
five copies of pIII. Polyvalent display has been used for rapid selection of antibodies as in 
the case for target discovery (115) and in the Selectively Infective Phage (SIP) system 
(84, 91).  
        
Figure 1.5: Representation of monovalent display of single chain Fv (scFv) displayed 
on pIII of M13 phage. Adapted from Adv.Drug.Deliv.Rev 2006 (124, 144) 
 
  Phage panning is the process of selection, enrichment and amplification used to 
isolate an antibody specific to a desired antigen via phage display. Antigen-specific 
antibodies displayed on phage are enriched by selective adsorption onto an immobilized 
scFv 
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antigen (immunotube or magnetic bead) and the bound phage is eluted by low pH, which 
is then amplified through infection of E. coli cells (Fig 1.4). Usually 4-6 rounds of 
panning are necessary to isolate antibodies specific to a desired antigen. 
  Phage display has been used to isolate antibodies from immune, naïve and 
synthetic antibody libraries. It also has been successfully applied towards the isolation of 
antibodies with high affinities or increased resistance to chemical or thermal 
denaturation, and in the direct selection against whole cells. 
Cell display: 
  Cell surface display of an antibody is a method which utilizes Fluorescence-
Activated Cell Sorting (FACS) as a tool for screening the library. This approach has been 
successfully used to screen antibody libraries by using bacteria, yeast and mammalian 
cells (Fig 1.6). In this method, cells displaying an antibody library are incubated with a 
fluorescently-labeled antigen and sorted through flow cytometry, which measures the 
fluorescence intensity of an individual cell. Cells are then collected depending on their 
fluorescence as a direct measure of the bound fluorescent antigen. FACS also takes 
advantage of real-time visualization for optimization of library screening and, in addition, 
it utilizes multiple fluorescence parameters for specificity or cross-reactivity during 
screening (30). The successful screening of fluorescent cells relies on factors such as, 




      
Figure 1.6: Representation of cell surface display of single chain Fv (scFv). Adapted 
from Adv.Drug.Deliv.Rev 2006 (144) 
 
a. Bacterial display 
  Escherichia coli (E. coli) is one of the most well studied organisms. Its rapid 
growth rate and ease of genetic manipulation make it a model organism for bacterial 
display. However, successful display on bacterial cells depends primarily on the size and 
folding efficiency of the protein. The first method of bacterial display developed, 
employed the fusion of a scFv antibody gene to Lpp-ompA for display of antibodies on 
the bacterial surface. This method could enrich scFv-displaying cells from control cells 
by using FACS (46), and was later used successfully for affinity maturation studies (31). 
In an effort to combine cell display and phage display, the Lpp-ompA system was also 
used to capture scFv-displaying phage by antigen displayed on the cell surface(9). 
However, the method is limited by the size of the antigen that can be bound by the 
displayed antibody, because lipopolysaccharide (LPS) on the E. coli surface interferes 
with the binding of antigen.  
scFv 
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  A more versatile system with antibodies displayed on the inner membrane was 
developed by our group, namely Anchored Periplasmic Expression (APEx). The method 
utilizes a fatty acylated lipoprotein sequence – NlpA, fused to the antibody fragment to 
be displayed to facilitate the anchoring of the protein on the periplasmic side of the inner 
membrane (57). Following the disruption of the outer membrane of the cell by Tris-
EDTA-lysozyme treatment, cells are labeled with fluorescently tagged antigen and 
screened by using FACS. Antibody genes are recovered from sorted cells via PCR and 
subcloned; the process is repeated until enrichment is achieved. This method has been 
successfully used for the affinity maturation of scFvs (57, 58) as well as to engineer 
scFvs that fold in the absence of disulfide bonds (143). A variation of this method the 
APEx-2-hybrid system, involves an antigen expressed as an epitope -tagged soluble 
periplasmic protein. The antigen bound to the inner membrane-anchored antibody is 
detected by fluorescent anti-epitope tag antibody following disruption of the outer 
membrane(78). This approach has also been used for the engineering of an IgG-display 
system(113). 
b. Yeast display 
  Display of antibodies on the surface of S. cerevisiae is achieved by the fusion to 
the Aga2p adhesion receptor, which anchors the complex to the cell wall. Yeast cells 
expressing fusion proteins are then labeled with fluorescent antigens and analyzed by 
flow cytometry. The eukaryotic expression machinery and the presence of certain post 
translational modifications give yeast display an added advantage over bacterial display 
systems. (87). The ability of yeast to form diploids via mating of haploid yeast and to 
 19 
efficiently recombine homologous DNA sequences has also been exploited to enhance 
the diversity of libraries (12, 161). One of the most successful applications of yeast 
display so far, has been in the isolation of high affinity antibodies. Moreover, one of the 
highest affinity antibodies (48 fM) reported so far was selected through yeast display 
(13). Yeast display has also been applied for screening of cDNA libraries and epitope 
mapping (126). 
In vitro display technologies: 
  In vitro display systems have become a valuable tool in the antibody engineering 
field. This system has made it possible to display libraries with a diversity of ~1014. In 
addition, it circumvents the constraints associated with display of toxic proteins. In the 
last decade, in vitro display libraries have been used successfully used to isolate high 
affinity antibodies, and have become an integral part of the antibody discovery platform. 
a. Ribosome display: 
  Ribosome display is among the first and the most widely used cell-free display 
systems and was first described by Mattheakis et al (111). The system is based on in vitro 
translation of proteins from a DNA library using cell-free expression systems. Following 
the translation of the antibody, the mRNA–ribosome–antibody complex formed is 
stabilized by low temperature and high salt concentrations, which stalls the ribosome at 




Figure 1.7: Representation of ribosome display of single chain Fv (scFv). Adapted 
from Adv.Drug.Deliv.Rev 2006 (144) 
 
These mRNA-ribosome-antibody complexes are screened against an immobilized 
ligand in selection steps and the complexes that bind well are then reverse transcribed to 
cDNA and amplified by PCR (144, 181). This method has been used for successful 
isolation of high affinity antibodies (79) and binders from immune libraries(55). 
b. mRNA display:  
            
   
Figure 1.8: Representation of mRNA display of single chain Fv (scFv). Adapted from 





  mRNA display is achieved by the formation of a complex between a polypeptide 
and its encoding mRNA generated by an in vitro translation via a puromycin linkage 
(138, 162).  Puromycin is a peptidyl acceptor antibiotic and an analogue of amino acyl 
tRNA. It interferes with the translation through entry into the ribosomal A site, and 
covalently binds to the nascent peptide (Fig 1.8). The mRNA–puromycin-peptide 
complexes are used for selection over immobilized targets, and are reverse transcribed to 
cDNA before the consecutive selection process (141). It has been successfully applied for 
the in vitro evolution of single chain antibodies(48). 
c. Covalent / non-covalent DNA display: 
  These methods exploit the in vivo cis-activity of replication initiation proteins to 
bind to its own template DNA. CIS display, described by Odegrip et al, uses the bacterial 
replication initiation protein RepA to bind to its template DNA following in vitro 
translation (122). Translated RepA interacts non-covalently with its origin of replication 
(Ori) due to the cis-element that causes ribosomes to pause during translation, leading to 
formation of DNA-protein complexes (Fig 1.9). 
              
Figure 1.9: Representation of DNA display of single chain Fv (scFv). Adapted from 




 Covalent antibody display (CAD) uses the bacteriophage endonuclease P2A 
because of its ability to covalently bind 5′ phosphate of its own DNA. Antibody libraries 
fused to RepA / P2A can be used for panning on an immobilized antigen. After 
enrichment, DNA can be recovered by PCR and used for subsequent cycles of panning 
(135). DNA display not only provides a direct link between a gene and its protein, but 
also avoids the use of highly degradable mRNA as in other in vitro display technologies. 
In addition, the system is very well suited for scaling up and automation. 
d. Antibody arrays: 
Antibody array is a new approach based on immobilized antibodies on an array as 
a high-throughput screening method to identify interacting antigens. The arrays not only 
enable the detection of targets in small sample volumes but also allow the multiplexed 
use of antibodies for efficient screening, where antibody targets can be screened in 
parallel. It has been successfully applied to cancer research for identification of 
biomarkers and measure expression of disease related proteins(53). 
Affinity maturation: 
  One way to enhance the therapeutic value of an existing antibody is to improve its 
affinity, which may allow for a reduced dosage for treatment. The two basic approaches 
for affinity maturation are random mutagenesis and focused mutagenesis. The selection 
of a mutagenesis strategy relies on the antibody, type of antigen and information 
available about their interaction. Random mutagenesis is the method of choice in the 
absence of structural information about antigen –antibody interaction. It closely mimics 
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the in vivo process of somatic hypermutation without focusing on any particular residue 
(103). Random mutagenesis can either be applied to an entire variable gene, or can be 
limited to CDRs. Mutagenesis is commonly achieved through DNA amplification by 
error prone PCR (19, 47). This method provides a better control over the mutation 
frequency, and low mutation frequency (<2% nucleotide substitution per gene) is favored 
for affinity maturation.  
  In chain shuffling the light chain of an antibody is initially shuffled with a library 
of light chains to select for a variant with improved affinity, and then the selected 
antibody is diversified further by shuffling with heavy chain libraries. This method has 
been successfully used to improve the binding affinity by 20-200 fold (109) and has been 
shown to work well when the starting antibody clone displays  low-affinity in the 
micromolar range. In in vivo mutagenesis, a bacterial mutant strain with an impaired 
mismatch repair system is used for propagation of the gene in order to generate a library 
of random mutants (75, 104) 
  Focused mutagenesis is a method, where in mutations are concentrated either on 
CDR residues or residues at the interface of the antigen-antibody complex. Usually either 
a crystal structure or a homology model of the antigen-antibody complex is used for 
identification of these residues. In CDR walking, randomization is focused to CDR 
regions(5, 182), and is accomplished either by error prone PCR or by using degenerate 
oligonucleotides. In another approach, CDR loops are extended to favor the contact 
between the antibody and antigen (93).  
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  Finally, DNA shuffling can be used to combine the beneficial mutations of clones 
isolated from a selection based either on random or focused mutagenesis, since in most 
cases these can be additive to give rise to a better antibody. 
Engineering valency , bispecificity and bifunctionality: 
  The use of antibody fragments such as Fabs, scFvs and single domain fragments 
have become an increasingly popular because of the ease with which they can be 
manipulated, and expressed.  However, antibody fragments are monovalent and lack the 
functional affinity (avidity) exhibited by IgGs. Therefore, various strategies have been 
used  to introduce bivalency or multi-valency to antibody fragments, such as crosslinking 
of Fabs by an introduction of cysteine in each fragment or creation of multimers by 
varying the linker length of a scFv(Fig 1.3)(1). 
 All naturally occurring antibodies are monospecific.  Nevertheless, antibodies 
generated through engineering can be made bi-specific, by introducing two different 
binding specificities in a single molecule. Bi-specificity can either be towards two 
adjacent epitopes on a single antigen thereby improving the avidity(34), or by 
crosslinking two different antigens(127).  
 Bifunctional antibodies combine the specificity of an antibody with a biological 
function encoded by either a chemically linked or fused partner (1). These include; (i) 
Antibodies conjugated to radioisotopes such as Ibritumomab and Tositumomab (both anti 
CD20 mAbs), which target B-cell tumors and induce cellular damage in the target and 
neighboring cells. (ii) Antibodies conjugated or fused to a bacterial toxin. For example, 
Gemtuzumab which targets CD33 expressed in 90% cases of acute myeloid leukemia 
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(AML) is linked to a cytotoxic agent from the class of calicheamicins. (iii) Antibodies 
conjugated to a polyethylene glycol (PEG) molecule as in the case of Certolizumab pegol 
– a humanized tumor necrosis factor (TNF) specific Fab, which increases the serum half 
life and reduces the immunogenicity (26). 
Fc engineering: 
  Engineering the Fc region (constant region) of an antibody has gained momentum 
in recent years, and is focused either on elimination or enhancement of the effector 
functions. In order to eliminate effector functions,  human IgG4 (3)or human IgG1 with 
either specific mutations (71) or removal of Asn297 – a conserved Fc glycosylation site 
(131, 163)have been pursued.  
  To enhance the effector functions by improving the affinity of Fc to Fc receptors 
(FcγRs), either mutagenesis and screening or computational design approaches has been 
used. By screening such Fc variants Lazar et al (95)isolated Fc that displays 100-fold 
better affinity towards FcγR, and two-three fold better antibody dependent cell mediated 
cytotoxicity (ADCC). Mutations that result in either 100-fold enhanced ADCC by 
improving FcγR binding (152), or improved CDC and C1q binding (72) have also been 
identified. In an entirely different approach, studies have been performed to change the 
composition of the carbohydrate moiety of IgG, which is essential for maintaining a 
functional Fc structure(160). It has been shown that absence of fucose results in  efficient 
ADCC without affecting other FcγRs interactions (145) and absence of sialic acid in a 
murine IgG display enhanced affinity for FcγR111 resulting in better effector function 
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(85). Finally, a number of Fc variants have been identified that exhibit enhanced affinity 
towards neonatal Fc receptors (FcRns) (170), which enhances the serum half life.  
  So far, Fc glycosylation has been deemed important for effector functions. 
However, attempts are being made to introduce effector functions to an aglyosylated 
antibody.  For example it was shown that modifications in the aglycosylated Fc domain 
result in the engagement of Fc gamma receptors (142). These results offer hope that it 
will be possible to produce full length IgGs with enhanced effector functions in bacterial 
systems, thus reducing the cost of antibody therapeutics. Nevertheless, these Fc 
modifications might also impact the immunogenicity of the antibody. 
 
PRODUCTION OF RECOMBINANT ANTIBODIES 
  Production scale of an antibody is determined by the intended application, which 
can range from grams per annum for diagnostics to 1,000s of kilograms per annum for 
therapeutics. In addition, the purity of an antibody required for therapeutics is highly 
stringent driving up its cost. The most challenging aspect of therapeutic antibody 
development in comparison to other biologics is that often high doses are required, 
resulting in a high cost to the patient. At present, all the monoclonal antibodies that are in 
the market are produced by mammalian cell culture. Thanks to recent developments, 
yields of antibodies in bioreactor of 5 g/l or higher are now routine (17). Advances in cell 
line generation, including expression vectors, transfection technologies and new cell lines 
have given a significant boost to the productivity of antibodies in mammalian culture. 
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Nonetheless, production costs are still high, leading researchers to seek out alternative 
expression systems such as yeasts, filamentous fungi, transgenic plants and E. coli. 
         Transgenic plants present an attractive and economical system for production of 
antibodies, as proteins produced in plants are regarded as safe (105). Even though plant 
expression systems can assemble functional full length immunoglobulins, they differ in 
their ability to glycosylate proteins relative to mammalian cells. Since the antibody 
glycans are quite heterogeneous , research is in progress to develop mutant plants with a 
humanized glycosylation pathway (172). 
      Yeast and filamentous fungi are attractive options for cost-effective large scale 
production of antibody fragments and antibody fusion proteins and are generally regarded 
safe. However, active proteases present in the yeast cells degrade antibodies, thereby 
reducing the yield (83). 
            E. coli expression systems so far have been limited to the production of antibody 
fragments, but research is underway in making the system more suitable for expression of 
full length IgG antibodies. The extensive knowledge of E.coli based protein expression 
and the ease of genetic manipulation makes it a desirable host for antibody production. 
Though expression levels exceeding 1-2g/L of scFv in fermentor has been observed (21), 
the system is limited by its unreliability and reproducibility as the expression may vary 
from batch to batch, and difficulty in producing functional antibodies. 
ANTIBODIES AND INFECTIOUS DISEASE 
  High specificity and recruitment of the immune system make antibodies excellent 
candidates to treat infectious diseases. However, of the 23 mAbs approved by the FDA 
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only one is an anti-infective (the anti-RSV antibody) (Table 1.1). The slow pace of the 
progress of antibody therapeutics towards infectious disease is due to the high cost and 
the necessity for early and precise diagnosis of the pathogen. With the emergence of 
novel viruses, antibiotic resistant micro-organisms, threat of bioterrorism, and fear of 
rapid spread of infection as a result of globalization interest in anti-infective antibody 
therapy has increased. (134).   
  Anti-viral antibodies have so far been clinically more successful in comparison to 
antibodies against other infectious diseases. Such antibodies can prevent infection 
through a variety of mechanisms. Antibodies can inhibit infection either by blocking 
various steps that virus takes to enter the cell, or by interfering with the internalization or 
release of virions (Fig1.10). 
              
    Figure 1.10: Mechanisms of viral neutralization by antibodies   a- Blocking 
receptor engagement by binding to spike, b-Blocking viral entry by binding to viral 
receptor, c and d – Blocking internalization of virus, e- Inhibition of release of virions. 
Adapted with permission from Nature Biotechnology (107) 
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  However, the exact mechanism of viral neutralization and the role of Fc-mediated 
effector function in clearance of viruses are still not clear and seem to be virus dependent 
(107, 124). Two different models for neutralization have been proposed: The occupancy 
model and the critical binding site model. According to the occupancy model, successful 
neutralization depends on the proportion of epitopes that are bound by the antibody on 
the virion in a linear fashion. Hence, the larger the virion, the higher the concentration of 
antibody required for neutralization. This model has been supported by neutralization 
studies of West Nile Virus (WNV), which showed efficient neutralization at higher 
concentrations, whereas antibody dependent enhancements (ADE) of infection at a lower 
concentration of antibody(129). Alternatively, the critical binding model focuses on the 
epitopes that are more critical for neutralization than the coating of the virus by antibody.  
  Many antiviral mAbs are currently under clinical development and some of them 
are listed in Table 1.2. Since one of the major challenges for developing successful anti-
viral antibody is rapidly evolving viruses that generate variants which escape 
neutralization; treatments with cocktails of mAb are also being pursued. Their synergistic 

























Table 1.2:  List of anti-infective antibodies in development. (Information from 
literature(107, 124) ) 
 
 As bacterial toxins have a direct role in the pathogenesis of bacterial infections, 
they form excellent candidates for antibody therapy. Anti-toxin antibodies neutralize 
toxin activity by either competing with the cellular receptor, or by blocking the substrate 
access  (124)(Table 1.2).These antibodies generally do not to require effector functions, 
as antibody fragments have been shown to be effective in the absence of Fc domain(106).  








mAbsShiga toxin 1 and 2 E. coli
Human Pertussis toxinB. pertussis
HumanToxins A & BC.difficile













Transgenic HuMab-mouseGlycoprotein antigenic site  I / II / IIIRabies
Humanized – IgG1Glycoprotein FRSV
AntibodyTargetsInfectious Agent
Human –igG1Envelope glycoprotein gbCMV
Human IgG1S1- RBDSARS
Humanized /  human -IgG1Envelope protein Domain IIIWest Nile Virus










  The development of anti-bacterial and anti-fungal antibodies is faced with many 
challenges and is less advanced in comparison to anti-viral and anti-toxin antibodies. For 
a viable therapeutic strategy and its success, identification of suitable targets is very 
important(124).  Targeting cell surface antigens that are either essential for the cell 
survival or for the recruitment of the host immune response are ideal candidates. 
However, variability among clinical isolates necessitates the development of isolate-
specific therapeutics raising the costs. It also exerts evolutionary pressure on the cells, 
potentially leading to the emergence of resistant isolates. On the other hand, targeting 
extracellular virulence factors and signaling molecules may prove to be a attractive 
approach(7). Several monoclonal antibodies are currently under development for 
treatment of both bacterial and fungal diseases (Table 1.2). 
Limitations  
  Even with the tremendous progress in the development of therapeutic antibodies, 
their role in prevention and treatment of infectious disease has been slow compared to 
other diseases. Antigenic variance and the emergence of antibody resistant variants have 
all played a role in hampering the development of antibody based therapeutics for 
infectious diseases. Furthermore, a major hindrance for the success of anti-infective 
antibodies has been the cost associated with antibody therapeutics. To have an advantage 
over other therapeutic approaches it is crucial for antibody therapeutics to be cost-
effective. We hope that with better understanding of pathogenesis combined with 
advances in antibody engineering will help in lower the costs, making antibody 




THE RELATIONSHIP BETWEEN ANTIBODY AFFINITY AGAINST SPIKE 
PROTEIN OF SARS-COV AND VIRAL NEUTRALIZATION 
 
INTRODUCTION: 
  Severe acute respiratory syndrome (SARS) is an infectious disease that set off an 
epidemic in late 2002 and early 2003, and turned out to be the first new infectious disease 
of the twenty first century. It is characterized by a rapidly progressive atypical pneumonia 
and its causative agent was identified after a concerted effort from researchers all over the 
world led by WHO, to be a novel coronavirus (CoV) termed SARS-CoV (110).   The 
virus first appeared in Guangdong province of China in November of 2002, and spread 
swiftly around the world. The ease of international travel due to globalization has been 
held responsible for the rapid spread resulting in more than 8000 cases across 33 
countries, with a mortality rate close to 10% (149, 175) The epidemic was effectively 
brought under control by July of 2003 by quarantine measures and travel restrictions (36, 
125). Since then only a few sporadic cases have been reported, which were caused by 
different isolates of SARS-CoV (101). The SARS epidemic has been divided into 
zoonotic, early, middle and late phases and refers to the timeline of the emergence of the 
disease (187).  
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  SARS-CoV is an enveloped, single-stranded positive sense RNA virus, whose 
structural proteins consist of the spike(S), envelope (E), membrane (M), and nucleocapsid 
(N) proteins (92, 110, 140). It is a zoonotic virus, considered to have originated from bats 
(94, 100) that crossed the species barrier and then spread mainly through respiratory 
secretions and by a person to person contact. SARS-CoV is known to primarily target 
cells in the respiratory system that express an abundant Angiotensin-Converting Enzyme 
2 receptor (ACE2)(99). After infection the virus enters and replicates in these cells, and 
the released matured virions infects new target cells (Fig: 2.1). SARS-CoV has also been 
shown to target mucosal cells of the intestine, tubular epithelial cells of kidneys, 












                 Figure 2.1: The lifecycle of SARS-COV (adapted with permission from Nat 
Rev. Microbiology ) 
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  The spike (S) protein of SARS-CoV is a ~180 kDa type 1 transmembrane 
glycoprotein that trimerizes to form the spike. The S protein has two functional domains: 
The N-terminal S1 domain that contains the receptor binding domain (RBD- 318-510 
amino acids) and the membrane anchored C-terminal S2 domain, which contains two 
heptad repeat regions (HR1 and HR2) (98) (Fig:2.2).  The entry of the virus into the host 
cell is mediated by binding of the RBD to ACE2 on host cells and subsequent 
conformational changes in S2 that facilitate membrane fusion (94). Genome analysis of 
different isolates of SARS-CoV revealed a high rate of evolution in the S protein with 
amino acid changes in the RBD region. These amino acid changes in RBD have played a 
major role in its ability to overcome species barrier, initially allowing animal-to-human 












Figure 2.2:  a- Schematic of the S protein, b- Crystal structure of RBD complexed with 






    Figure 2.3: Schematic representation of cross-species transmission of SARS-CoV.  
Adapted with permission from Nat Rev Microbiol (128) 
 
 
  The S protein is a highly immunogenic antigen and is responsible for inducing 
neutralizing antibodies and protective immunity against virus infection. It also has 
determinants for host specificity, cell tropism and pathogenesis. Because of its 
immunogenicity and its crucial role in infection by recognition of the host receptor, the S 
protein has become an important target for both vaccine and therapeutic development. 
Researchers have used both full length S protein and recombinant RBD to develop 
vaccines. The full length S protein when used as a vaccine has been shown to provide 
protective immunity in vivo, both as a DNA vaccine (183) and as a highly attenuated 
modified vaccinia virus Ankara(MVA) vaccine(11). Vaccination by the purified full 
length protein in the form of S trimer has been shown to induce neutralizing antibodies 
against different SARS-CoV isolates in a mouse model (61). The use of recombinant 
RBD either by immunization as a RBD-Fc or following in vivo expression from an 
adeno-associated virus (AAV) vector - (RBD-rAAV) has been shown to elicit 
neutralizing antibodies and to confer protection against SARS-CoV challenge (35, 37, 
62). Although most of these  vaccines induced neutralizing antibody responses against 
infection, vaccination of ferrets with rMVA-spike (recombinant vaccinia Ankara) 
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exhibited increased inflammation and vaccine-linked  hepatitis, raising  concerns over the 
safety and efficacy of these vaccines (29). 
  Different approaches have been taken to develop spike protein-based therapeutics. 
Peptides having either the RBD sequence (aa 471-503) (68), or RBD-binding motifs of 
ACE2 (aa 22-44 & aa 351-357)(54) have been shown to disrupt the RBD-ACE2 
interaction and to exhibit inhibitory activity towards SARS-CoV infection in vitro (36). 
In vitro inhibition of infection was also seen with peptides that either interfere with the 
cleavage of S protein (188), or block the HR1-HR2 interaction, thus inhibiting the fusion 
of the viral envelope with the host membrane (15). 
  The use of monoclonal antibodies (mAbs) that block S protein from binding to the 
receptor is an attractive approach for passive immunization and for short-term protection 
against infection. Even though highly potent neutralizing mouse mAbs to RBD have been 
generated, the risk of human-anti mouse antibody (HAMA) responses prevents these 
from being an effective human therapeutic. To avoid this problem, a wide range of 
neutralizing human mAbs have been isolated from B cells of patients infected with 
SARS-COV(118, 167), from transgenic mice encoding the human immunoglobulin locus  
immunized with S protein(28), or from a non-immune human antibody library screened 
by phage display (158). Most of the isolated antibodies were successful in preventing the 
binding of SARS-CoV to ACE2 receptor and thereby neutralizing the infection in vitro. 
Some of these antibodies like 80R, m396 (189), 201 and 68 (51) have been shown to 
exhibit protection against infection in the mouse model.  Specifically, the 80R antibody 
was isolated from a non-immune human antibody library by phage display.  The scFv 
form of 80R was reported to exhibit an affinity of 32nM to S1 protein, as measured by 
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Surface Plasmon Resonance (158). Marasco et al.  found that  the neutralizing epitope of 
80R overlaps the ACE2-RBD domain and that not only it neutralizes SARS-CoV in vitro, 
but also effectively reduces the viral titers in vivo(159). 
  Even though there have been no reported cases of SARS after 2004, threat of re-
emergence is still present because of the presence of coronavirus in animal reservoirs. 
Antibody therapy provides an attractive approach for both prophylaxis and treatment. It is 
known that the potency of an antibody in viral neutralization is dictated by its epitope 
specificity, the dose (concentration) and half life in the blood stream. Both antibody 
affinity and valency have a strong influence on biological activity, with increasing 
affinity often resulting in higher neutralization potency (112). The concentration of 
antibody can also have an impact on viral neutralization, and the number of antibodies 
required for neutralization may be directly correlated to the size of the virus (16). In their 
study, Pierson et al. observed that neutralization is a function of both affinity and epitope 
accessibility, and lower concentration of weak neutralizing antibody might lead to 
antibody-dependent enhancement (ADE) of infection (129). However, recent studies with 
antibodies against RSV reported high affinity related non-specific tissue binding that led 
to very poor bio-distribution in vivo (180). This study suggests that functional 
improvement observed in vitro because of high affinity may not always translate to 
improvements in vivo. The mechanisms of viral neutralization vary among viruses, and a 
high affinity neutralizing antibody (nAb) directed towards a critical epitope constitutes an 
attractive strategy in designing therapeutic anti-viral antibody. 
  One of the major obstacles in treating RNA-viruses is the random mutations that 
drive the antigenic drift. As described before, amino acid changes in the spike protein 
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have been found to be responsible for the ability of SARS-CoV to cross the species 
barrier. The generation of neutralization escape mutants from studies with nAbs, and the 
presence of zoonotic strains that evade neutralization signifies the need for broad 
neutralizing antibodies (BnAbs) for protection against a range of viral strains. In their 
efforts towards isolating BnAbs, Dr. Marsaco and his group sought to isolate improved 
variants of the 80R antibody by utilizing structural information from 80R-RBD complex 
to guide the construction of mutant libraries targeting the light chain. Screening of these 
libraries by phage display against RBD protein containing the dominant mutations found 
in  escape variants (D480A and D480G) led to the isolation of antibody variants  
exhibiting broad neutralizing ability(157).  However, the broadly neutralizing antibodies 
reported in this work exhibited only about 3-fold higher affinity for the Urbani strain 
RBD protein to which the starting antibody, 80R had been raised. The above findings 
raise the question, whether antibody variants of 80R displaying greatly improved affinity 
might elicit broader neutralization.  In one scenario, high affinity might result from 
increased binding energy to multiple residues within the binding epitope.  If so, a single 
mutation of the spike protein within that epitope might be sufficient to allow escape.  
Alternatively high affinity might arise from more favorable interaction to a single residue 
or “hot spot” and thus mutations in the hot spot or in other residues within the binding 
epitope might result in escape.    
 In this research, we explore the relationship between affinity towards the viral 
antigen and the evolution of escape mutants.  The 80R antibody was affinity matured by 
random mutagenesis and screening using the bacterial display technology Anchored 
Periplasmic Expression or APEx (57). After just one round of random mutagenesis and 
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screening by APEx, we isolated antibodies with 140-fold higher binding affinity.  DNA 
shuffling and mutagenesis of the best clones followed by additional screening resulted in 
a further increase in antigen affinity to ~ 300-fold relative to the parental scFv antibody, 
80R.  These high affinity antibodies were shown to exhibit increased neutralization 
potency in vitro against the wild-type Urbani strain compared to the parental antibody 
80R, validating the critical role of affinity in viral neutralization. However, the affinity 
matured antibody fragments were ineffective against zoonotic strains of SARS-CoV, 
suggesting that a high affinity towards RBD alone is not sufficient to provide broad 
protection against different isolates of SARS-CoV.  On the other hand SK4, our highest 
affinity antibody fragment could neutralize SARS-CoV mutants that either evaded 
neutralization by 80R or could escape other lower affinity antibodies.  
 
MATERIALS AND METHODS: 
Bacterial Strains and Plasmids: 
  Escherichia coli Jude 1 [DH10BF::Tn10] cells were used for all the cloning and 
protein expression experiments reported here. Plasmid pAPEx 1 was used for N-terminal 
APEx display of scFv, and the construction of scFv libraries (57). pMopac 16 encodes a 
pelB leader followed by Sfi 1 sites and  the Skp chaperone that helps in soluble 
expression of protein into periplasmic space, a C-terminal constant human kappa light 
chain  for scAb expression and C-terminal 6 x Histidine tag for easy purification (59). 
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Viruses and Cells1:  
  Recombinant viruses’ icUrbani (AY278741), icGD03-MA and icHC/SZ/61/03 
were propagated in Vero E6 cells. Vero E6 was maintained in MEM media (Invtirogen, 
Carlsbad, CA) supplemented with 10% Fetal Clone II (Hyclone, South Logan, UT) and 
gentamycin / kanamycin (UNC Tissue Culture Facility). Growth curves were performed 
in Vero E6 with the different wild type or mutant recombinant-derived escape mutant 
viruses at a MOI of 0.1 for 1 hour and overlaid with medium. Virus samples were 
collected at various time points post infection and stored at -70ºC until viral titers were 
determined by plaque assay.   
  Virus titers were determined as plaque forming units (pfu) by plating 6-well plates 
with 5x105 Vero E6 cells per well and inoculating cultures with 200 µl from the 10-fold 
serial dilutions. Cells were incubated with the virus for 1 h at 37ºC and overlayed with 3 
ml of 0.8% agarose in complete media. Plates were incubated for 2 days at 37ºC and 
plaques were visualized by staining with neutral red for 3-6 h. Virus concentration was 
calculated as pfu /ml. All virus work was performed in a Class II biological safety cabinet 
in a certified bio-safety level 3 laboratory containing redundant exhaust fans while 
wearing Tyvek suits and Powered Air Purifying Respirators. 
Construction of ScFv Library: 
  The 80R single chain antibody gene (158) was constructed by overlap extension 
PCR (153). The heavy and light chain variable regions of the antibody were amplified by 
PCR, and a flexible (Gly4 Ser)4 linker introduced by overlap PCR. The amplified 80R 
                                                 
1  All in vitro viral neutralization experiments were conducted by Dr. Ralph Baric (UNC). 
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scFv PCR product was digested with Sfi1 and cloned into the Sfi1-digested pAPEx 1 
vector (57) for bacterial display.  The 80R scFv gene was subjected to random 
mutagenesis by error-prone PCR using standard protocols.  A library of 1.6 x 108 
independent transformants was obtained. Sequencing of 10 random clones revealed a 
nucleotide substitution rate of 1.3% (47). 
Cloning, Expression and purification of Receptor Binding Domain: 
  A gene encoding the S protein of the SARS-CoV Urbani strain (AY278741) was 
generously provided by Dr. S. Makino (UTMB-Galveston), and used to amplify the 
receptor binding domain (RBD) consisting of amino acids 318 to 518. The RBD was 
cloned into pFastbac vector (Invitrogen) with the N-terminal Honeybee Mellitin signal 
sequence (164) for secretion in insect cells and a C-terminal Flag tag for screening and 
N-terminal 6 x Histidine tag for purification.  Bacmid DNA was prepared and transfected 
into SF9 cells (Invitrogen) according to the manufacturer’s (Invitrogen – Bac-Bac 
system) instructions to generate and amplify baculovirus particles, and the titers were 
determined by following the Bac-Bac protocol. High five cells (Invitrogen) were cultured 
in Insect Xpress media (Cambrex, Walkersville, MD) supplemented with 10% fetal 
bovine serum (Sigma) and Penicillin/Streptomycin (Sigma) at 27°C as a monolayer. To 
produce RBD, insect cells were seeded at a density of 106/ml in 250 ml of media and 
infected at a multiplicity of infection of 5 with recombinant RBD baculovirus. Media 
were harvested after 90 hours, and the culture supernatant was dialyzed against 1x IMAC 
buffer at 4°C.  Following dialysis, the culture supernatant containing the RBD protein 
was incubated with 1ml of nickel-nitrilotriacetic acid (Ni-NTA) agarose (Qiagen, Hilden, 
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Germany) for 2 hours at 4°C. The mixture was then loaded onto a 5 ml column, and 
washed with 10 column volumes of 1x IMAC buffer (10mM Tris. 0.5M NaCl pH 8.0). 
Protein was eluted with 3 column volumes of 1 x IMAC buffer with 300 mM imidazole. 
The protein eluate was further purified on a superdex-200 (GE Healthcare) size exclusion 
column via FPLC. Protein samples were analyzed for purity on a 4-20% polyacrylamide 
gel (NuSep, Lawrenceville, GA) and stained with coomassie blue stain. 
Screening and Selection of high affinity ScFv variants by APEx: 
  E. coli strain Jude 1 cells transformed with the 80R scFv library in the pAPEx 1 
vector, were used to inoculate shake flask containing 20 ml of terrific broth (TB) media 
(Difco, Sparks, MD)) supplemented with chloramphenicol (Cm) at 35 µg/ml to an OD600 
of 0.1. Cells were grown at 37°c with shaking until the OD600   reached 0.5, at which point 
cultures were transferred to a 25°C shaker for 30 min.  Protein synthesis was induced 
with IPTG to a final concentration of 1mM, and incubation was continued for 3 hours at 
25°C with shaking. 2-3 ml of cells equivalent to an OD600 of 10 were collected by 
centrifugation and resuspended in 350 µl of ice-cold Tris- sucrose (0.75 M Sucrose and 
0.1 M tris-HCl pH 8.0) solution with 30 µl of 40 µg /ml lysozyme. An additional  700 µl 
of ice-cold 1 mM EDTA was added drop-wise and the mixture was incubated at 4°C on a 
rotary shaker for 15 min. 50 µl of 0.5M MgCl2 was then added and incubated for another 
10 min at 4°C on a rotary shaker. Cells were then gently pelleted and resuspended in 1 ml 
1x PBS with purified RBD (100 nM for the first round) and incubated for 40 min at room 
temperature on a rotary shaker. Subsequently, the cells were pelleted again and 
resuspended with 1x PBS containing 200 nM anti-FLAG-PE (Phycolink – Prozyme, San 
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Leandro, CA), at room temperature for 40 min. After labeling, the cells were pelleted to 
remove the excess label, resuspended in 1ml 1x PBS and analyzed on a FACS ARIA (BD 
Biosciences) flow cytometer using 488 nm for excitation. The spheroplasted cells were 
gated based on forward scatter (FSC) and side scatter (SSC) parameters, 5% of the most 
fluorescent cells were collected and the sort population was resorted immediately. scFv 
genes in the resort solution were amplified by PCR, cloned into the pAPex 1 vector,  the 
ligation mixture was transformed into E. coli strain Jude 1 cells and plated on LB agar 
plates containing chloromphenicol at 35 µg/ml. Cells were scraped from the agar plates, 
and was used for inoculation into liquid media and then subjected to additional three rounds 
of sorting as above, with decreasing concentration of RBD to increase the stringency of 
sorting as follows 100 nM in the first round; 50 nM in the second;25 nM in the third and 20 
nM in the final round.  
   After the fourth round of sorting via FACS, genes were rescued by PCR and 
cloned into pMopac16 (60) for soluble expression. For high throughput screening based 
on off-rates, colonies were inoculated into 96 well seed plate containing 200 µl of TB 
with 2% glucose and 200 µg/ml ampicillin per well. After overnight growth at 37°C with 
shaking, 20 µl of the culture from each well was used to inoculate fresh 96 well plates 
with same growth media as above.  The seed plate was stored with 15% glycerol at -20°C 
for future use. After overnight growth at 37°C with shaking, cultures were pelleted by 
centrifugation at 4,500 rpm for 10 min. The media were discarded and cell pellets were 
resuspended in 200 µl of expression media (TB with 200 µg/ml ampicillin and 1 mM 
IPTG), and incubated at 25° C for 3 h. The cells were pelleted again by centrifugation at 
4,500 rpm for 10 min, resuspended in 200 µl of lysis buffer (20% bugbuster HT-Novagen 
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in HBS-EP buffer) and incubated with shaking at room temperature for 2 hours. The 
lysates were centrifuged to precipitate the insoluble fraction, and the lysate supernatant 
was transferred to a 96 well Multi screen HTS filter plate (Millipore, Billerica, MA) set 
on a collection plate,  centrifuged for 10 min and clarified filtrate was collected in a 96 
well collection plate.  The clarified filtrate was used for off-rate (koff) analysis by SPR 
using a BIAcore 3000 instrument (GE Healthcare, Uppsala, Sweden) as follows: Purified 
RBD was first Covalently immobilized in 10mM Sodium acetate, pH 5.9 on to a CM5 
sensor chip (carboxymethylated dextran matrix-GE Healthcare, Uppsala, Sweden) by 
using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide / N-hydroxy succinimide chemistry 
to the level of 300RUs (Response units). BSA was similarly coupled to the chip as an in-line 
subtraction standard. Kinetic analysis was performed in HBS-EP buffer (GE Healthcare, 
Uppsala, Sweden) at a flow rate of 25 µl/min at 25 ºC. Samples were injected over the 
immobilized RBD for 2 min followed by a 5 min dissociation phase. The surface was 
regenerated by injection of 10 µl of 4 M MgCl2 at a 50 µl/min flow rate. Dissociation 
kinetics were calculated using BIA evaluation software, and clones with slowest 
dissociation rate compared to 80R were selected for further analysis. 
Shuffling and random mutagenesis of isolated clones for additional screening: 
  The four highest affinity scFv genes (B9, F10, RS2 & RS5) isolated from the off-
rate analysis above along with the 80R scFv gene were chosen for DNA shuffling. The 
four isolated genes were first amplified individually by PCR and the DNA products were 
pooled with a 4 molar excess of 80R scFv and then digested with 0.125 U of DNase I 
(Roche, Germany) per 3 µg of DNA at room temperature for 30 min. The reaction was 
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stopped by heat inactivation at 80°C for 10 min and  DNase I digest fragments of 50–100 
bp were gel-purified using the QIAEX II (Qiagen) gel extraction kit. The DNA fragments 
were re-assembled by PCR for first few rounds without primers, and then full length 
DNA was amplified using outside primers encoding Sfi1 site.  DNA was separated by gel 
electrophoresis and a band ~750 bp in length was excised and gel-purified using the 
Qiagen gel extraction kit (Qiagen), then digested with Sfi1 and ligated to Sfi1 digested 
pApex 1 vector. Following electroporation 5.4 x 107 transformants were obtained. Ten 
clones were chosen at random and sequenced to evaluate the presence of mutations from 
different templates, suggesting that DNA shuffling had been successful. PCR product 
after the assembly was also used as a template for error prone PCR as above, and the 
DNA product from that reaction was cloned into pApex 1 vector to generate a library of 
1.5 x 107 transformants. 
  The shuffled library and the shuffled + error prone libraries above were combined 
for FACS screening, and three rounds of sorting were performed as described above. The 
concentration of RBD used for labeling was reduced in successive rounds as follows: 20 
nM for the first round; 10 nM for the second round and 5 nM for the final round. After 
the final round of sorting, scFv genes were PCR amplified and sub cloned into pMopac 
16.  Subsequently, 96 colonies were inoculated for high throughput screening, and cell 
lysates were prepared and analyzed by BIAcore for off-rates as described before. 
Expression and purification of single chain antibody fragments (scAbs): 
  Antibody fragments were expressed as scAbs by inserting the scFv genes into 
pMopac16 vector, a pAK400 derivative in which the scFv is fused in frame to a C-
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terminal human constant kappa domain. pMopac16 also co-expresses the Skp periplasmic 
chaperone which aids in the expression of soluble antibody fragments (60). ScAbs are 
expressed as fusions with a C-terminal 6x his tag for easy detection and purification. 
  Antibody fragments were expressed in E. coli Jude1 [DH10BF::Tn10]. Individual 
colonies were inoculated into 50 ml TB media with 200 µg/ml ampicillin and 2% 
glucose, and were grown overnight at 37°C. The overnight cultures were used to 
inoculate 500 ml of TB media with 200 µg/ml ampicillin and the cells were grown at 
37°C for 3 hours.  Cultures were transferred to 25°C for 30 min and protein expression 
was induced with 1 mM IPTG.  After a 4 h incubation at 25°C, cells were collected by 
centrifugation and protein was purified from the osmotic shock fraction (60, ).  Briefly, 
cells were resuspended in 12 ml of ice cold Tris-sucrose solution (0.75 M sucrose, 100 
mM Tris pH 8) with the addition of 1 ml of 30 µg/ml lysozyme in Tris-sucrose buffer. 
Cells were gently mixed for 10 min at 4°C, 24 ml of 1 mM EDTA was added dropwise 
and was allowed to mix for an additional 20 min at 4°C. 1.7 ml of 0.5 M MgCl2 was 
added and incubated for further 10 min. The samples were centrifuged at 12,000 rpm for 
15 min, and the resulting supernatant was dialyzed against 1x IMAC buffer (10 mM Tris. 
0.5 M NaCl pH 8.0). ScAbs were purified from the supernatant using IMAC 
(immobilized metal affinity chromatography) column, by using Ni-NTA agarose 
according to maufacturer’s protocol (Qiagen, Hilden, Germany), followed by size 
exclusion FPLC on Superdex 200 (GE Healthhcare) as explained earlier. The purity of 
isolated scAb was verified by gel electrophoresis on a 4-20% SDS-PAGE gel (NuSep, 
Lawrenceville, GA) stained with coomassie blue. 
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  To remove the endotoxin from the purified scAbs for in vitro neutralization 
assays, the purified protein samples were passed three times through Detoxi-gel 
endotoxin removal columns (Pierce, Rockford, IL) according to the manufacturer’s 
instructions. The endotoxin levels in the samples were measured by the Limulus 
Amoebocyte Lysate (LAL) assay (Associates of Cape Cod, East Falmouth, MA) as 
described by the manufacturer.  
 
BIAcore analysis for affinity measurement: 
   The purified RBD protein was immobilized on CM5 chip as described above and 
BSA was used as in-line subtraction. Kinetic analysis was performed in HBS-EP buffer at a 
flow rate of 50 µl/min at 25°C. The affinity of the FPLC-purified scAbs was analyzed by 
injecting the samples over the chip for 2 min for the association phase followed by 5 min 
dissociation. Five different concentrations of antibodies from 9 nM-36 nM were analyzed in 
duplicate, along with a blank as a reference. The surface regeneration was performed with a 
12 sec injection of 4 M MgCl2. Binding kinetics were calculated using BIA evaluation 
software (GE Healthcare, Uppsala, Sweden). Calculated fits were based on the Langmuir 1:1 
model, with chi2 values below 1. 
Isolation of Escape Mutants:  
   Recombinant icUrbani used as seed stocks for deriving RS2, RSK, SK4 and 80R 
escape mutants. Briefly, 1 x 106 pfu of icUrbani were incubated with 20 µg of a 
neutralizing scAb (RS2, RSK, SK4 or 80R) for 30 mins and then inoculated onto cells in 
the presence of scAb at a concentration of 20 µg/ml. The development of cytopathic 
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effect (CPE) was monitored over 72 hrs and progeny viruses harvested. Antibody 
treatment was repeated two additional times and more rapid CPE noted with each 
passage.  The viruses from passage four were plaque purified in the presence of antibody 
and neutralization resistant viruses were isolated. The S glycoprotein genes from four 
individual plaques for each neutralization experiment were sequenced and the 
neutralization titers between wild type and antibody-resistant viruses were determined as 
described below. 
  In the experiment above, the SK4 scAb resulted in the extinction of parent viruses 
on three separate occasions.  Therefore, we incubated 1 x 106 PFU of icUrbani with 15, 
10, 5 and 1 µg of SK4 for 30 mins, and then infected cultures in the presence of 5 µg/ml 
SK4 antibody. Depending on treatment conditions, cytopathology was evident either 
within 48 h (5, 1 µg doses) or was minimal after 4 days (15 and 10 µg).  Low dose SK4 
treated progeny viruses (1 and 5 µg doses) were treated with 5 µg of SK4 for two 
passages, and then selected with one additional treatment of 10 and 15 µg doses, resulting 
in highly antibody resistant viruses that produced extensive CPE in cultures within 24-36 
hours.   High-dose treated stocks were passaged once in the absence of antibody (pass 2) 
to restore virus titers, and then reselected two times in the presence of 5µg antibody.  
Two final treatments of 10 and 15 µg of SK4 antibody resulted in highly resistant 
populations that rapidly produced CPE in culture.  Two to four plaques were isolated 
from each treatment regimen (10 plaques total) in the presence of 20 µg SK4 antibody 
and the S glycoprotein gene was sequenced.  
 49 
Plaque Reduction Neutralization Assay (PRNT): 
    30 µg of each scAb in the panel (80R, RS2, RSK, and SK4) were diluted into 50 
µl and diluted 1:2 into PBS.  Wild-type icUrbani, icGD03-MA and icHC/SZ/61/03 and 
various recombinant viruses were diluted and approximately 100 PFU of each in 175 µl 
was added to the scAb dilution series for 30 mins at 37°C. The percentage neutralization 
was calculated as 1- (number of plaques with antibody / number of plaques without 
antibody) X 100.   
 
RESULTS: 
Expression and purification of the RBD portion of the SARS-CoV S glycoprotein: 
    Marasco and coworkers had shown that recognition of RBD by the 80R antibody 
is glycosylation independent.  Therefore, initially we made efforts to express the 
aglycosylated RBD in bacteria. We cloned RBD in various expression vectors either as a 
fusion protein with MBP or GST or alone. Though we were successful in expressing and 
purifying the RBD polypeptide, it was found to not bind to the 80R scFv. Therefore, we 
chose to express RBD in the Baculovirus system (Fig 2.4). The expression yield of RBD 
in High Five cells was around 1.2 mg/L of insect cell culture.  Following purification the 
RBD domain was found to be >95% pure as determined by SDS-PAGE and gave a strong 
signal on ELISA with 80R scFv.    
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Figure 2.4: A- ELISA results for baculovirus purified RBD protein detected by 80R 
scAb. M18scAb was used as negative control. B- Western blot analysis for baculovirus 
expressed RBD .The protein was detected by anti-spike polyclonal antibody. 
 
 Random mutagenesis and affinity maturation of the 80R scFv: 
  Random mutagenesis by error-prone PCR was employed to construct a library of 
variants of the 80R scFv. Following transformation of the ligated DNA by 
electroporation a total of 2x108 transformants were obtained with an average of 1.3% nt 
substitutions per gene. Cells were grown in liquid culture, and after the protein 
expression was induced for 4 h, the cells were harvested and converted to spheroplasts. 
The spheroplasts were incubated with 100 nM RBD for 40 min, followed by labeling 
with 200 nM anti-FLAG -PE. A total of 4 x 108 cells were sorted and 5% of the 
spheroplasts with the highest fluorescence were collected and resorted. The scFv genes 
from the sorted cells were rescued by PCR amplification and were re-cloned into pApex 
1. Following transformation, the cells were subjected to three additional rounds of 
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the concentration of antigen from 100 nM RBD in the first round to 20 nM in the final 
round. An increase in the percentage of fluorescent cells was observed after 3 rounds of 
sorting (Fig 2.5).  After round four, scFv genes were rescued by PCR and cloned into 
pMopac 16 for soluble expression.  
 
  







Figure 2.5: Comparison of FC histograms of library with the 3 successive rounds of 
sorting, showing enrichment in the fluorescence. M= Mean fluorescence intensity  
 
  Since the enrichment of high affinity clones by the Apex screening method 
presumably relies on relative dissociation rates, antibodies with higher affinity can 
generally be identified by measuring off-rates (koff) by Biacore. As koff is not 
concentration dependent, it was possible to set up a high throughput screen to measure 
koff without purifying the antibody fragments. A total of 88 randomly picked colonies 
from the round 4 and 8 colonies of 80R scAb as a control was grown in a 96-well plate. 
Expression of antibody fragments was induced with IPTG and the soluble fraction was 





















(HBS-EP) to reduce the effects on the refractive index during analysis. Lysates were 
filtered using a 96-well filter plate, to remove the cell debris which may interfere with 
SPR measurements. The filtered lysates were used for SPR analysis, and the koff was 
calculated using the BIACORE software. The koff values were compared to the parental 








     
 
                                                           
   
              Figure 2.6: BIAcore analysis of scAbs in cell lysates. Data for four clones 
exhibiting slower dissociation rates compared to parental 80R clone are 
shown  
 
The four clones with the slowest antigen dissociation kinetics were produced in 
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filtration FPLC to remove any scAb dimers. SPR analysis of the purified proteins 
revealed that they all exhibit significantly lower KD values for RBD binding compared to 
the parental 80R antibody and that the improvement in KD values are primarily from 
slower koff, as anticipated (57)(Fig 2.6). The affinities of the scAb variants ranged from 
0.78 nM to 0.103 nM, with the highest affinity clone RS2 exhibiting a KD of 103 pM and 
a koff of 1.7 x 10
-4 sec-1 which corresponds to a RS2-RBD complex half life of 1 h (Fig 
2.7). This represents a > 140-fold improvement compared to the parental antibody 80R 
(KD = 15.9 nM). 
  Sequence analysis of the isolated clones revealed the presence of 5-8 amino acid 
substitutions per scFv gene, with RS2 possessing 8 amino acid substitutions (Fig 2.7). 
Most of the amino acid substitutions were present in the framework regions, with only 
one consensus mutation, S167N, observed in the CDR1 light chain of all four clones 
(data not shown). S167 is located at the interface of the co-crystal of 80R-RBD complex 
(70) indicating its possible involvement in RBD binding. The significance of this 
mutation was recently highlighted by Marasco and coworkers (157) who reported that 
S167N is important for broad neutralization of SARS-CoV Urbani strain variants 











        ----------FR1-----------------  -CDR1  ------FR2-----  -----CDR2--------  ---- 
                                                                                                  
        ....|....|....|....|....|....|  ....|  ....|....|....  |....|....|....|.  ...| 
80R    EVQLVQSGGGVVQPGKSLRLSCAASGFAFS  SYAMH  WVRQAPGKGLEWVA  VISYDGSNKYYADSVKG  RFTI  
RS2    .......D.........Q............  ...T.  ..............  .......S.........  ....  
B9     ..............................  .....  ..............  .......D.........  ....  
RS10   .....R.................T......  G....  .........P....  .................  ....  
G5     ..............................  G....  ..............  .......S.........  ....  
 
 
        -----------FR3--------------  --CDR3--  ----FR4----  ------- LINKER -----  --- 
                                                                                                 
        ....|....|....|....|....|...  .|....|.  ...|....|..  ..|....|....|....|..  ..| 
80R    SRDNSKNTLYLQMNSLRAEDTAVYYCAR  DRSYYLDY  WGQGTLVTVSS  GGGGSGGGGSGGGGSGGGGS  TTL  
RS2    ...........R................  ........  ....A......  ....................  ...  
B9     .......A....................  ........  .......A.R.  ..............P..SD.  ...  
RS10   ............................  ........  ...........  ....................  ...  
G5     ............................  ........  ...........  .............SG...~.  ...  
 
 
        -------FR1---------  ---CDR1----  -----FR2-------  -CDR2--  ----------FR3----- 
                                                                                                 
        ....|....|....|....  |....|....|  ....|....|....|  ....|..  ..|....|....|....| 
80R    TQSPATLSLSPGERATLSC  RASQSVRSNLA  WYQQKPGQAPRPLIY  DASTRAT  GIPDRFSGSGSGTDFTLT  
RS2    ...................  .......N...  ...............  ..N....  ..................  
B9     I..................  .......N...  ...............  .......  ..................  
RS10   ...................  .......N...  ...............  .......  ..................  
G5     ...........D.......  .......N...  ...............  .......  ..................  
 
 
        --------------  --CDR3---  --------FR4--------- 
                                                              
        ....|....|....  |....|...  .|....|....|....|... 
80R    ISRLEPEDFAVYYC  QQRSNWPPT  FGQGTKVEVKSASGAEFAAA  
RS2    ..............  .........  ....................  
B9     ..............  .........  ....................  
RS10   ..............  .........  ....................  
G5     ..............  .........  ....................  
 
0.34 5.20 +  0.03 x10-4 1.51 +  0.02 x 106 RS5 
0.48 7.40 +  0.05 x10-4 1.52 +  0.03 x 106 RS10 
0.10 1.70 +  0.01 x10-4 1.66 +  0.02 x 106 RS2 
0.78 9.14 +  0.11 x 10-4 1.16 +  0.04 x 106 RS9 
15.9 1.30 + 0.04 x 10-2 8.20 +  0.04 x 105 80R 
KD(nM) kd(1/s) ka(1/Ms)   
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Figure 2.7:  Sequence alignments of clones RS2, RS10, B9 and G5 with 80R Affinity 
data for the four clones in comparison to parental 80R along with the standard deviations 
for the fit are provided in the table.  
  To investigate if other amino acid substitutions, in addition to S167N, have a 
beneficial role in improving the antigen affinity and also to eliminate neutral mutations, 
clones B9, RS2, RS5, F10 and the parental 80R were subjected to DNA shuffling 
followed by random mutagenesis by error-prone PCR. The 80R scFv was used in 4 molar 
excess for DNA shuffling in order to reduce the number of neutral mutations. Two 
libraries were constructed: A shuffled library with 5.4 x 107 members and an error-prone 
library of 1.5 x 107.mmbers. Ten random clones from both libraries were sequenced to 
verify the shuffling between the templates in the shuffled library and to calculate the 
approximate nucleotide substitution in the second library, which was 0.5%. Both the 
libraries were pooled for screening and the combined library was sorted by FACS. The 
stringency of screening was further increased by reducing the concentration of antigen 
from 20 nM in the first round to 5 nM in the third round. After the third round of sorting, 
scFv genes were rescued by PCR and cloned into pMopac16 for soluble expression as 
scAbs. The antigen dissociation rate constants of 80 scAbs from clones picked at random 
from the 3rd Round were analyzed by SPR analysis and two clones with slower off-rates 
were identified (data not shown). Both clones were further produced in a preparative 
scale from 500 ml liquid cultures, and purified proteins were used to measure KD values. 
Antibody variant SK4 exhibited a KD value even lower than RS2, equal to 45 pM, and a 
koff of 8.05 x 10
-5 sec-1, resulting in an antigen: antibody complex half-life of 2.2 h (Fig 
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2.9, Table 2.1). Overall, the SK4 antibody fragment is more than 300-fold affinity 
enhanced compared to the parental fragment 80R. Sequence analysis of SK4 revealed 12 










    
                 Figure 2.8: Comparison of FC histograms depicting the mean fluorescence 
intensity (M) of the selected high affinity clones RS2 and SK4 with 80R.  
 
  To determine the role of the N57S, S167N and S188N amino acid substitutions in 
affinity enhancement, the respective mutations were introduced into 80R scFv by site 
directed mutagenesis to construct a variant referred to as RSK (Fig 2.11). SPR analysis of 
RSK revealed a KD value equal to be 220 pM, which is lower than 80R, indicating a role 
for some or all of these three amino acid substitutions (N57S, S167N and S188N) in 
affinity improvement (Fig 2.9, Table 2.1). Clearly, however, this is not the whole story as 













































Figure 2.9: BIAcore analysis of purified anti-RBD scAb proteins on immobilized RBD. 


















































Table 2.12: Rate constants and equilibrium dissociation values for the antibodies 
isolated from the library as measured by SPR . Standard deviations for 
the fit as measured by the software are provided. 
                                                 
2  Affinity values for clones 80R, RS2 and SK4 are from two independent measurements. Affinity value for 
RSK is from a single measurement. 
0.22 1.76 + 0.02 x 10-4 7.89 + 0.01 x 105 RSK 
0.045 8.05 +  0.14 x 10-5 1.77 + 0.02 x 106 SK4 
0.10 1.70 +  0.01 x10-4 1.66 +  0.02 x 106 RS2 
15.9 1.30 + 0.04 x 10-2 8.20 +  0.04 x 105 80R 
KD (nM) kd (1/s) ka (1/Ms)  Clone 
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Figure 2.10: Sequence comparison of the high affinity clones RS2, SK4, and RSK 
with parental 80R clone. 
 
       
 
                10          20        30         40         50         60         
      ....|....|....|....|....|....|  ....|  ....|....|....  |....|....| 
80R   EVQLVQSGGGVVQPGKSLRLSCAASGFAFS  SYAMH  WVRQAPGKGLEWVA  VISYDGSNKYY  
RS2   .......D.........Q............  ...T.  ..............  .......S...  
SK4   ..R...........................  G....  ..............  .T.....S...  




                 70         80        90        100         110        120    
      ....|.  ...|....|....|....|....|....|...  .|....|.  ...|....|..  ..| 
80R   ADSVKG  RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR  DRSYYLDY  WGQGTLVTVSS  GGG  
RS2   ......  ...............R................  ........  ....A......  ...  
SK4   ......  ........G..A....................  ........  .........N.  ...  




               130         140       150         160       170         180     
      ....|....|....|..  ..|....|....|....|....  |....|....|  ....|....| 
80R   GSGGGGSGGGGSGGGGS  TTLTQSPATLSLSPGERATLSC  RASQSVRSNLA  WYQQKPGQAP  
RS2   .................  ......................  .......N...  ..........  
SK4   ..........~......  ...I..................  .......N...  ..........  




               190         200        210        220        230        240     
      ....|  ....|..  ..|....|....|....|....|....|....  |....|...  .|....| 
80R   RPLIY  DASTRAT  GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC  QQRSNWPPT  FGQGTKV  
RS2   .....  ..N....  ................................  .........  .......  
SK4   .....  ..N....  ........N.......................  .........  ....A..  




            250  
     ....|....|... 
80R  EVKSASGAEFAAA  
RS2  .............  
SK4  .............  
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Figure 2.11: Interface of structure of the RBD-80R complex .  S1-RBD is in blue, 
CDR loops (H1-H3 and L1-L3) of 80R, mutations N57S, S167N, S188N 




















Neutralization assay and generation of escape mutants: 
  The neutralizing ability of the purified 80R, RS2, SK4 and RSK scAbs against 
SARS CoV (Urbani strain) was tested by plaque reduction assay. Approximately 100 
PFUs of wild type icUrbani strain were incubated at 37°C for 30 min with a serial 
dilution of each of the 4 scAbs using a starting concentration of 30 µg in 200 µl. The 












    Figure 2.12: Neutralization activity of the four scAbs tested by plaque reduction 
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  These experiments revealed that, as expected, the neutralization potency of the 
antibodies increased with affinity with SK4 and RSK exhibiting higher neutralization 
potency (Fig 2.12).  However, none of the scAbs could neutralize icHC/SZ/61/03 (a Civet 
strain) or icGD03MA (a mouse adapted human 03/04 strain, data not shown). The spike 
protein of these strains differs from that of the icUrbani strain at 6 amino acid positions 
within the RBD region (Table 2.2). Evidently, these mutations play a crucial role in 







       Table 2.2: Amino acid differences in the RBD region of the spike protein in 
different strains of SARS-COV 
  In vitro neutralization escape mutants of the icUrbani strain that emerged 
following incubation with each of the four scAbs mentioned above were obtained. After 3 
passages in cell culture with antibody, 4 plaques were picked for analysis. RNA isolated 
from the plaques was used to amplify the RBD cDNA by RT PCR and sequenced.  All 
the four escape mutants of 80R and RS2 had a single amino acid mutation at position 
480. Three of the four 80R-escape mutants carried a mutation from aspartic acid to 


























(D480Y).  The four RS2 escape mutants had the D480Y mutation. In the case of the RSK 
antibody, three of the four escape variants had the D480Y mutation and one had mutation 
at position 436 with an amino acid change from tyrosine to histidine (Y436H) (Table 
2.3).  
  The SK4 antibody exhibited a very high neutralizing potency and did not generate 
any escape variants, unlike the other three antibodies. Therefore, conditions were 
modified by decreasing the initial concentration of SK4 scAb used for incubation. The 
cytopathic effect (CPE), as observed by detectable morphological changes in the host cell 
due to infection with icUrbani strain was evident and robust in the virus treated with 
lower concentration (5 µg, 1 µg) of antibody in the initial passage . Virus treated with the 
higher concentration (15 and 10 µg) of antibody in the initial round showed minimal CPE 
after 4 days, and therefore viral titer had to be restored in the absence of the antibody in 
the second passage. 
        A total of nine out of ten plaques that were isolated from different treatment 
regimens with SK4 were sequenced.  All the 9 escape mutants of the SK4 antibody had 
two mutations: N479I and D480Y (Table 2.3). The presence of mutations at position 
D480 in most of the escape mutants was not surprising, since it has been shown to have a 
critical role in the binding of the parental antibody 80R to the RBD (70). D480 is the 
most common residue to undergo mutation as has been observed before (159), and 
substitution to a Tyrosine does not affect the binding of the RBD (and therefore the virus) 
to the human ACE2 receptor (178).  
  Cross-neutralization studies with mutant virus particles encoding either D480A or 
the D480Y that mediated escape from 80R and its derivatives were performed with all 
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four antibodies (Fig 2.13). Only the SK4 antibody successfully neutralized both escape 








                  Table 2.3:  Amino acid changes in the RBD of spike protein found in the 
neutralization escape mutants generated by scAbs.  












































Figure 2.13: Cross neutralization studies of the four scAbs with escape mutants. A. 









0 .1 1 1 0































































































  SARS was the first new major infectious disease to challenge the world 
population in the twenty first century. Though the number of deaths resulting from the 
disease was smaller compared to previous pandemics such as plague, influenza, or the 
mortality of other infectious diseases such as HIV, malaria or tuberculosis, the 
widespread fear and resulting travel restrictions eventually resulted in a global economic 
loss of about 59 billion dollars (187), emphasizing the role of globalization in the spread 
of the disease and also its effect on the global economy.  Collaborative efforts from 
researchers all over the world were successful in controlling the epidemic in a short 
period of time. One of the main focuses of research efforts has been to develop 
neutralizing antibodies that could be used for both prophylaxis and therapy. Of the many 
neutralizing antibodies that have been developed, the one against the RBD region of the 
spike protein has been shown protective by blocking its binding to the host cell receptor 
in both in vitro and in vivo studies(158, 159, 189). However, the use of neutralizing 
antibodies for the prevention and treatment of infectious diseases, especially in the case 
of possible pandemics, is restricted by the related issues of production limitations and 
cost. One way to tackle these problems is to improve the neutralization potency of the 
antibody; thereby reducing the dosage required and thus making it more cost-effective 
while simultaneously easing production requirements.  
In the present study, we investigated the role of affinity in enhancing the 
neutralization potency of the 80R antibody. For affinity maturations, we employed the 
APEx bacterial display system for the screening of libraries of random mutants.  The 
screening of a large library of random mutants resulted in the isolation of antibody 
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variants that bind to the RBD region of the spike protein with affinities ranging from 0.78 
nM to 0.1 nM, the latter corresponding to a 140-fold improvement in affinity.  We were 
able to further improve the binding affinity of the best clones from the random 
mutagenesis library by additional mutagenesis via DNA-shuffling combined with a round 
of random mutagenesis.  Screening of the resulting library led to the isolation of the SK4 
antibody which exhibits a monovalent antigen affinity of 45 pM (Table 2.1), representing 
a roughly 300-fold improvement over wild-type 80R. Only one consensus mutation, 
S167N in the CDR1 of the light chain, was observed in all the isolated affinity-improved 
antibodies.  In addition, two more common mutations, N57S and S188N, were observed 
in the high affinity antibody clones RS2 and SK4 (Fig 2.7). We introduced these three 
consensus mutations into the 80R parental antibody to generate construct RSK.  RSK 
displayed a substantial affinity improvement indicating that these three amino acid 
substitutions play a significant role in decreasing the dissociation rate of the 
antigen:antibody complex, without affecting the association rate. Clearly, other mutations 
present in RS2 and SK4 are making contributions as well.  
In vitro neutralization studies revealed that as expected, higher affinity leads to 
greater neutralization. The high affinity antibody SK4 along with RSK exhibited the 
highest neutralizing potency against the icUrbani strain (Fig 2.8). It has been shown 
previously that the 80R antibody fails to neutralize SARS-CoV strains with the D480A/G 
mutation in their RBD (158). In their recent study, Dr. Marasco and coworkers screened 
and isolated antibodies based on a criterion of broad neutralizing ability of SARS-CoV 
strains with D480A/G mutation, and observed the presence of the S167N mutation in all 
the isolated antibodies suggesting it has possible role in broad neutralization (157).  
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In order to determine if high affinity along with the presence of S167N mutation 
will help in neutralization of various strains, our antibodies were tested against strains 
HC/SZ/61/03 and GD03MA (Table 2.2). All the antibodies failed to neutralize these 
strains (data not shown) suggesting that neither high affinity nor the S167N mutation was 
sufficient for neutralization of these strains. 
  To further understand the potential role affinity might play during simulated 
infection, the anti-RBD antibodies were used at sub-neutralizing concentrations in order 
to generate viral escape mutants. Sequencing revealed that the most common RBD 
mutation observed in the escape mutants generated by all four antibodies was D480Y.  A 
D480A mutation in RBD was observed in the case of 80R, and a Y436H mutation in 
RBD was seen in the case of the RSK antibody.  For SK4, the highest affinity antibody in 
the study, all the escape mutants generated had an N479I mutation combined with 
D480Y. Cross neutralization studies revealed that SK4 successfully neutralized the 
escape mutants generated with either the D480A or D480Y mutation, suggesting a 
critical role of N479I in escape of neutralization from SK4 antibody.  It remains to be 
seen whether this result is due to overall enhanced affinity, wherein more RBD mutations 
are required to inhibit SK4 binding below a critical neutralization threshold affinity, or 
whether N479I is specifically counteracting a unique SK4 interaction with RBD. 
 On an entirely different level, it is important to point out that the mutations 
present in the escape mutants could very well represent mutations that might appear in 
future viral strains.  It is therefore of value to catalogue these changes, as well as develop 




Consistent with expectations, enhanced antibody affinity was correlated with 
neutralizing potency against the wild-type Urbani SARS strain. However, our studies 
indicate that high affinity on its own is not enough to protect against other viral strains 
and escape mutants.  It is important to keep in mind that all of our studies were conducted 
with antibody fragments, and it is likely that bivalent IgG’s will increase the potency of 
neutralization.  Studies with whole IgG’s are currently in progress and will be reported in 
due course.  
  All of the high affinity antibodies used in this study were isolated after just one 
round of random mutagenesis using our bacterial display system. As such, the results 
have affirmed the reliability of the bacterial display system for antibody affinity 
enhancement in general, and in particular, for the production of neutralizing antibodies to 
RBD protein. In the future, one can imagine creating a panel of high affinity antibodies 
using RBD antigens from different strains of virus. Cocktails of these high affinity 
antibodies might be sufficient to provide protection against multiple viral strains 
encountered in future SARS outbreaks.  
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ISOLATION OF ANTIBODIES AGAINST BURKHOLDERIA MALLEI AND 




  Burkholderia pseudomallei and Burkholderia mallei are non-spore forming, rod 
shaped, pathogenic Gram-negative bacteria that belong to the Burkholderia genus. They 
are the causative agents for the diseases melioidosis and glanders, respectively. At 
present, there are no vaccines available and both species are resistant to many antibiotics 
(86); hence treatment is limited to few antibiotics and requires a long-term regimen. 
Moreover, the potential for the pathogens to cause disease through inhalation of aerosols 
has resulted in classifying them as a category B agent (potential bio-threat agent) by the 
Center for Disease Control (CDC)(14).     
 B. pseudomallei is a natural saprophyte and is found in soil and water, which are 
the natural reservoirs of the bacteria. It is the causative agent of melioidosis in humans, 
and is endemic in Thailand, parts of Southeast Asia, northern Australia and South 
America (74). Although a rare disease in the developed countries, the number of cases 
that have been diagnosed has been increasing, due to rise in travel to endemic areas. The 
spectrum of infection in humans varies from the sub-clinical to fatal septicemia and 
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immunocompromised individuals were more susceptible to the disease. Currently, the 
isolation of the bacteria from clinical samples is the only reliable method for diagnosis. 
However, a delay in identification of the organism due to its slow growth can prove fatal 
in cases of acute infection, especially septicemia. Hence for an adequate onset of therapy, 
rapid and reliable diagnosis is required. The diagnostic value of serological based testing 
like ELISA, immunoblot, hemagglutination and immunoflourescence have so far been 
limited is unreliable in endemic areas (73). In addition, the application of PCR based 
testing has been limited due to lack of appropriate controls and the high incidences of 
false positives (190). Furthermore, the disease cannot be readily diagnosed by clinical 
manifestations alone due to flu-like symptoms(173) (176). Though melioidosis can be 
treated with an aggressive regimen of antibiotics, relapse rates are very high and 
mortality rate associated with septicemia is 40%.(14) 
  B. mallei is a non-motile, obligate mammalian pathogen that causes the zoonotic 
disease glanders. It usually infects solipeds, such as horses and mules. Human infections 
are rare, and only people in direct contact with the infected animals were found to be at 
most risk. A person to person spread of B. mallei is extremely rare (155). B. mallei is 
highly infectious as an aerosol, and inhalation can lead to septicemia, pulmonary 
infection or chronic infections of the muscle, liver and spleen. The disease has a mortality 
rate of 50% when treated with antibiotics, and 95% when untreated (174). As with 
melioidosis, diagnosis is made primarily through culture detection. In addition, the 
mallein test is a specific clinical test used in animals(116). Other serological tests and 
PCR detection are also used, but have not been validated yet.  
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           The genomes of both Burkholderia species have been sequenced and each 
organism has two chromosomes (64, 119) The large chromosome carries genes 
associated with cell growth and metabolism, where as the smaller chromosome carries 
genes associated with adaptation and survival (64). Both species have a highly 
homologous genome, and B.mallei is not only a deletion derivative but also a clone of B. 
pseudomallei as revealed by MLST analysis (49). Both organisms are facultative 
intracellular bacteria, and exploit the host cell to promote their intracellular replication 
and survival. Since they reside within the cytosol of the bacteria, it provides them with a 
means of protection from the humoral immune system, thus making it difficult to 
overcome an established infection. 
               Though the pathogenesis of Burkholderia is not well understood, some of the 
mechanisms are deduced because of its similarity to other intracellular organisms. The 
life cycle of cytosolic bacteria can be divided into three stages: escape from the vacuole, 
replication within the cytosol and manipulation of the innate immune responses triggered 
in the cytosol (132). The invasion of non phagocytic cells by B. pseudomallei have been 
found to be dependent on a type III secretion system (TTSS)(156). Following their entry 
into the eukaryotic target cells, intracellular survival becomes crucial for bacteria as they 
can be destroyed by autophagy- a pathway by which lysosomes destroy the intracellular 
pathogens. To promote their survival, cytosolic bacteria interact with and modify the 
autophagy pathway. It has been observed that B. pseudomallei mutants lacking TTSS 
effector BopA (homologue of Shigella IcsB) are preferentially targeted to 
autophagosomes and show reduced survival indicating that this bacterial protein is 












 Figure 3.1: Intracellular lifestyle of B.pseudomallei adapted with permission from 
Nature Reviews Microbiology (176) 
a. Invasion of cells with the help of Burkholderia secretion apparatus (bsa) system 
b. Endosome escape and intracellular proliferation 
c. Cell to cell spread using actin based membrane protrusions 
d. Cell fusion – multinucleated giant cells 
 
  Bacteria escape from the endocytic vacuoles into the cytoplasm after 
internalization. Once in the cytoplasm, polymerization of actin at one pole of the 
bacterium drives its intracellular motility. The motility of these bacteria leads to the 
formation of protrusions on the host cell membrane that project into adjacent cells, which 
are engulfed and lysed by neighboring cells. This results in the intracellular spread of the 
infection, and evasion of immune surveillance. In B. pseudomallei the actin-based 
motility in murine macrophages was eliminated by a bimA mutation and was restored by 
transient expression of the gene in trans indicating a crucial role of BimA in actin tail 
formation (154).  
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  Many putative virulence factors have been listed for Burkholderia, and are mainly 
identified based on their role in virulence of similar pathogens. Genes associated with the 
quorum sensing, type III secretion system, capsular polysaccharide, lipopolysaccharide, 
flagella and siderophore are some of the putative candidates that are under investigation 
for their relevance to the disease (176).  
  The surface molecules of the bacteria not only form the interface between the 
organism and the host, but also play an important role in its pathogenicity. Several 
surface immunogenic proteins of B. pseudomallei have been identified by a proteomics 
based approach, in which a biotinylation approach was used to detect  surface proteins, 
which were later screened with immune human sera to identify immunogenic proteins 
(56, 179).  The highly immunodominant Hep_Hag autotransporter proteins have also 
been identified through screening of bacteriophage expression libraries from both species 
(166). Recently, microarray technology has been used to screen and identify 
immunogenic antigens from B. pseudomallei (40).  
 The intracellular lifestyle of the bacteria makes both antibiotic treatment and 
vaccine development challenging. There are several approaches that have been taken 
towards developing vaccines, which include using killed whole cells, live attenuated 
cells, LPS and capsular polysaccharide and recombinant proteins (14).  However none of 
these agents could provide full protection from challenge in an animal model of infection. 
Passive protection using mAbs has been evaluated and was shown to delay the death of 
BALB/c mice infected with B. mallei (168) or with B. pseudomallei (82).  However, 
these antibodies could provide protection only at the initial stage of the infection, and 
failed at later stages presumably due to the intracellularization of the bacteria. The role of 
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LPS and capsular polysaccharides as subunit vaccine candidates against B. pseudomallei 
have also been evaluated and were found to delay the time of death in mice but did not 
provide protection against challenge via the aerosol route (117).  Several other mAbs 
against LPS of B. pseudomallei have been used for immunological detection, but they 
have not been specific enough to discriminate between different species (190) 
   Antibiotic therapy is usually successful with early diagnosis of melioidosis, but 
the relapse rate is very high. The use of antibodies for either diagnosis or therapeutics of 
melioidosis and glanders has so far been limited. Antibodies which are bactericidal or 
promote phagocytosis can play an important role in the initial clearance of the organism. 
In addition, antibodies to other bacterial components or cellular mechanisms may also 
contribute to protective immunity as the infection progresses (63).  
       In general, the success of anti-bacterial antibodies so far has been limited 
primarily to anti-toxin antibodies. Identifying suitable candidate targets for passive 
immunization has been a major limitation in developing effective antibody therapies. In 
the case of Burkholderia, many surface-associated immunogenic proteins and virulence 
factors have been identified, and we sought to isolate antibodies against some of these 
targets. By screening for antibodies to a wide array of antigens, we hope to be able to 
select suitable candidate antibodies that can be used for either diagnostic or therapeutic 
purposes. These antibodies can also be used as tools for understanding the pathogenesis 
of these bacteria. 
 For decades, the traditional approach for the generation of antibodies has been the 
use of the hybridoma technology, which relies on immunization of animals. In the past 15 
years, there has been a considerable progress in the field of antibody engineering, with 
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the development of in vitro immune repertoires and selection platforms that can be used 
to isolate antibodies. These technologies provide with an attractive alternative to 
hybridoma technology. 
   Highly diverse synthetic antibody libraries where diversity is introduced into the 
CDRs via degenerate synthetic DNA into a selected highly stable and well-expressed 
framework have been developed. Considerable progress has been made in constructing 
highly functional synthetic antibody libraries. One such attempt was made by restricting 
the CDR diversity to amino acids serine and tyrosine, because of the bias towards these 
amino acids found in natural CDRs (10, 42, 89). By introducing additional diversity in a 
stepwise manner to the above mentioned binary coding library, Dr. Sidhu and his 
colleagues have constructed a rationally designed synthetic Fab antibody library with 
more than >1010 members(41, 43). They have used phage display as a selection platform, 
and have successfully isolated antibodies with low nanomolar affinity against a wide 
range of protein antigens. 
   In our efforts to isolate antibodies to a broad range of antigens from both B. 
pseudomallei and B. mallei, we used the above mentioned synthetic antibody library in 
combination with phage display. In this chapter, the successful isolation of antibodies by 
phage display to a range of antigens from B. pseudomallei and B. mallei is presented.  
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MATERIALS AND METHODS: 
Bacterial strains and antigens: 
  Escherichia coli XL1 Blue Strain (Stratagene, La Jolla, CA) was used for all the 
phage amplification and panning experiments and was grown in 2x TY media (BD Difco, 
Sparks, MD).  
  All the purified antigens used for screening experiments were provided by Dr. 
Annie Gnanam, Dr. Omar Qazi, and Dr. K. A. Brown, University of Texas –Austin. List 
of the antigens and the respective expression vectors are summarized in Table 3.1. All 
antigens with a histidine tag were purified using Ni-NTA followed by size-exclusion 
FPLC. Antigens fused to glutathione-S-transferase (GST) were purified using a 









                  Table 3.1:  List of antigen targets used for panning experiments. 
Synthetic antibody library: 
  A synthetic Fab phage display library, which expresses a bivalent Fab2 by virtue 
of a disulfide linkage at the hinge region, was obtained from Dr. S. Sidhu (University of 
Toronto). The library was constructed using a single highly stable Fab framework from a 








Hypothetical protein (64) 25.6 pET15B / N- 6x His tag 
BPSL2748 
(B. pseudomallei) 




Intracellular motility protein A 
(119)   










type III effector protein 
IpaD/SipD/SspD (64) 
59.12 pGEX-4T1/ GST Fusion 
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Figure 3.2: Design of the synthetic antibody library. 
(B) CDR diversity designs- At each diversified position, the allowed amino acids are 
denoted by the single-letter code. X indicates positions at which denoted amino acids 
were allowed.  
In the case of CDR-L3, the four positions were replaced by loops containing 3-7 residues. 
In the case of CDR-H3, the seven positions were replaced by all loop lengths between 1 
and 17 residues.  
 
(C) Theoretical and actual library diversities.  
 









(A) The backbones of a MBP specific Fab and 
heavy and light chain variable domains are shown 
as tubes. The frameworks are colored grey, and 
the CDR loops defined by Kabat et al. are colored 
as follows: CDR-H1, yellow; CDR-H2, orange; 
CDR-H3, red; CDR-L1, green; CDR-L2, blue; 
CDR-L3, purple. Positions that were diversified in 
the libraries are shown as spheres. Figure adapted 
w i t h  p e r m i s s i o n  f r o m  J M B  ( 4 1 ) 
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determining Regions (CDRs)(41). The diversity introduced in all the heavy chain CDRs 
and light chain CDR3 as shown in Fig 3.2. The theoretical diversity of the library is 1x 
1029, but actual diversity of the library is 3x 1010. 
Phage Library amplification: 
    The Fab synthetic antibody library was provided in the form of 6 sub-libraries of 
frozen phage stock with a titer of ~1011 /ml per sub-library. Each sub-library consists of 
varying loop lengths in CDRH3. In order to amplify the library for the panning 
experiments, 0.5 ml of each sub library was diluted with 0.5 ml of PBS with an addition 
of ¼ volumes of PEG/NaCl (20% PEG 6000, 2.5M NaCl) for precipitation and was left 
on ice for 30 min. The samples were centrifuged for 15 min at 13,000rpm. The phage 
pellet was resuspended in 1 ml PBS, and all the six phage sub-libraries were pooled and 
used to infect 5 L of exponentially growing XL1 Blue cells in 2x YT media. After a 30 
min incubation at 37°C, the culture was co-infected with M13K07 (NEB, Ipswich, MA) 
helper phage at 1:20 bacteria / phage ratio and the cells were incubated for 30 min at 
37°C. Following co-infection, carbenicillin (carb) at 50 µg/ml and kanamycin (kan) at 35 
µg/ml was added and cells were grown overnight at 30°C at 250 rpm for phage 
propagation. The following day cells were harvested by centrifugation at 10,000 rpm, and 
the phage from the media supernatant was rescued by precipitation with an addition of ¼ 
volume of PEG/NaCl. Following incubation on ice for 1 h, the phage precipitate was 
collected by centrifugation. The phage precipitate was resuspended in 40 ml of PBS, and 
precipitated again with the addition of PEG/NaCl. Following the second round of 
precipitation, phage precipitate was resuspended in 20 ml of PBS. Finally, the 
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supernatant containing the bacteriophage particles was filtered (pore size, 0.45 µm) prior 
to storage with the addition of 15% glycerol at −80°C. The phage titer was determined by 
serial dilution of infected E. coli (XL1 Blue) plated on 2x YT agar supplemented with 50 
µg/ml of carbenicillin.  The phage titer was calculated from the number of colonies and 
found to be around 1014 cfu /ml. Aliquots of the amplified phage were stored in -80°C. 
Phage panning using immunotubes: 
  Purified protein antigens (BPSL1549, BPSL2748 and BimA) were used at 100 
nM concentration (50 nM for 2nd round and 25 nM for 3rd round) to coat NUNC maxisorp 
immunotubes, in a 50 mM sodium carbonate buffer pH 9.6 overnight. Immunotubes were 
blocked with 2% milk PBS for 2 h at room temperature. A depletion step was performed 
before each panning round by incubating the phage library (1012-1013 cfu) in 2% milk 
PBS in a BSA (10 µg/ml) coated immunotube. Following the depletion step, the phage 
library in 2% milk PBS was added to the immunotube coated with the appropriate antigen 
and incubated for 2 h at room temp. Immunotubes were washed five times with PBST 
(PBS+ 0.05% Tween 20) and five times with PBS to remove the non-specifically bound 
phage (10 washes each for 2nd round and 15 washes each for 3rd round). Bound phages 
were eluted by incubating with 1 ml of 0.1 M triethylamine (TEA) for 15 min while 
rotating and were neutralized with 0.5 ml of 1 M Tris-HCl, pH 7.5. 0.75ml of the eluted 
phage was used to infect 10 ml of XL1 Blue cells in mid-log phase for 30 min at 37°C 
without shaking. Phage titers were determined as before, and the infected cells were then 
transferred to 40 ml 2x YT media with 50 µg/ml carb and were grown overnight at 30°C 
with shaking. The next day, cells were collected by centrifugation and resuspended in 5 
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ml 2x YT +50 µg/ml carb+ 15% glycerol, and were stored in -80°C. For phage 
amplification, cells were inoculated to an OD600 of 0.3 and infected with helper phage 
M13KO7 and grown overnight, and phage was precipitated by PEG/NaCl as described 
before. For each antigen target, library was panned for three rounds before screening for 
binders by ELISA.  
Phage panning using magnetic beads: 
  Purified protein antigens (BPSL1549, BPSL2748, BopE and BipD) were 
biotinylated using Biotin-NHS-SS (Pierce, Rockford, IL) according to the manufacturer’s 
instructions.  
  A depletion step to remove phage that bind to biotin was performed for each 
round of panning using streptavidin dynabeads (M-280, Invitrogen, Carlsbad, CA) as 
follows. 100 µl of streptavidin beads were washed twice with 1 ml of PBS, followed by a  
single wash with 1 ml of PBST (PBS + 0.05% Tween 20). Beads were then blocked with 
2% milk PBS for 30 min while rotating. To avoid the enrichment of biotin specific phage 
antibodies, biotinylated DsbC protein was added at a concentration of 5 µg/ml to the 
blocked beads and incubated for 30 min while rotating. The blocked beads were then 
washed once with PBS, and incubated with around 2x 1012 phage particles from the 
library in 2% milk PBS for 1h while rotating. For depletion of glutathione S-transferase 
(GST) specific phage antibodies, purified GST at 10 µg/ml was added to the above 
mixture. This phage was used for the following panning procedure. 
  The phage from the depletion step was incubated with 20 µg/ml biotinylated 
antigen (BPSL1549, BPSL2748, BopE and BipD) for 1 h in 2% milk PBS while rotating. 
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The phage – protein mixture was then added to a fresh batch of blocked 100 µl of 
streptavidin beads for 30 min while rotating. Following incubation, beads were washed 6 
times with PBST and 3 times with PBS to eliminate non-specific and weak binders. The 
bound phages were eluted by incubation with 1 ml of 100 mM triethylamine (TEA) for 
15 min, and neutralized by the addition of 0.5 ml of 1 M Tris pH7.4 buffer. 0.75 ml of 
eluted phage was incubated with 10 ml of XL1 Blue cells in mid-log phase at 37°C for 30 
min without shaking. Following infection, a cell aliquot was plated in serial dilution for 
titer determination.  The remainder of the cell solution was inoculated into 40 ml of 2x 
TY with 50 µg/ml carb, and was grown overnight at 30°C. The following day, cells were 
harvested by centrifugation and resuspended in 5 ml of 2x TY with 50 µg/ml carb and 
15% glycerol. Aliquots of cells were stored at -80°C. Phage amplification was performed 
as described above. 
   For the successive round of panning, the concentration of antigen was decreased 
from 5 µg/ml for the 2nd round to 1 µg/ml for the 3rd round. All incubation steps were 
performed at room temp. During washing and elution steps, beads were collected using a 
magnet. Typical yield of phage after each round of amplification following a panning 
round were 1013 cfu/ml, and around 1012 phage particles were used for successive round 
of panning. 
 Phage ELISA: 
   Monoclonal phage ELISAs were performed with individual clones to identify 
target specific binders. Single colonies from round 3 titer plates were inoculated in 96-
well plates (Costar-3790 Corning, Lowell, MA) containing 200 µl of 2x YT with 50 
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µg/ml carbenicillin and  grown overnight at 37°C. 30 µl of the overnight cultures were 
used to inoculate fresh 96-well plate containing 200 µl of 2x YT +50 µg/ml carb + 
M13KO7 (1010phage/ml), and grown overnight at 30°C for phage propagation. 50 µl of 
the culture supernatant containing the phage was used for ELISA. 
  100 µl of 20 µg/ml of antigens (BPSL1549, BPSL2748, BimA, BopE and BipD) 
in PBS buffer, and BSA at 10 µg/ml as control used to coat 96 well ELISA plates 
(Corning) overnight at 4°C. Plates were blocked with 2% milk PBS for 2 h at room temp, 
and washed once with PBS. 50 µl of the culture supernatant containing phage diluted 
with 50 µl of 2% milk PBS was added to each well. Each phage solution was tested for 
binding to both specific antigen and to the negative control BSA.  After a 2 h incubation 
at room temperature, wells were washed 3x in PBST and once with PBS. 100 µl of anti-
M13 HRP antibody (Pharmacia) in 1:1000 dilution in 2% milk PBS was added to each 
well, and incubated for 1 h at room temperature. Following incubation, wells were 
washed 3x PBST and 1x with PBS. For detection, 100 µl of TMB substrate (Dako, 
Carpinteria, CA) was added to each well, and incubated for 20-30 min, until the color 
developed. The reaction was stopped by the addition of 100 µl of 4.5 M H2SO4, and was 
read at 450 nm in a microtiter plate reader.  
  For sandwich ELISAs, phage antibody was prepared by growing phagemid 
containing cells in 30 ml of 2x YT + 50 µg/ml carbenicillin to exponential phase, and 
infected with M13KO7 helper phage. Infected cells were grown overnight and phage was 
purified by PEG/NaCl precipitation and resuspended in 2 ml PBS. A 100 µl solution was 
used to coat 96-well ELISA plate at 4°C overnight. After blocking the wells with 2% 
milk PBS for 2 h, serial dilution of each antigen was added with a starting concentration 
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of 40 µg/ml and incubated at room temperature for 2 h. Following washing as described 
before, 100 µl anti-His HRP(Sigma) in 1:5000 dilution for the detection of his tagged 
proteins (BPSL2748 and BimA). Following incubation for 1 h, wells were washed and 
detected by the addition of TMB substrate as described before. 
 
RESULTS: 
Isolation of B. mallei and B. pseudomallei specific antibodies: 
 A total of five protein antigens were selected for antibody isolation (Table 3.1). 
The protein BimA is a B. mallei protein, whereas the other four proteins BPSL1549, 
BPSL2748, BipD and BopE were from B. pseudomallei. All the proteins were provided 
by Dr. Annie Gnanam and Dr. Omar Qazi (University of Texas), and were >90% pure as 
determined by SDS-PAGE (Fig: 3.3).  
                  





                  Figure 3.3: Purified antigens run on a  4-20% SDS-PAGE   
















  The synthetic antibody library provided by Dr. S. Sidhu (University of Toronto) 
was used for panning experiments. The library contains > 3x 1010 members (Fig 3.2). The 
library was panned against select antigens from both B. mallei and B. pseudomallei using 
two different selection strategies, either by immobilization on immunotubes or in 
suspension following biotinylation and capture by streptavidin beads. 
   For panning experiments using immunotubes, three antigens BPSL1549, 
BPSL2748 and BimA were immobilized on immunotubes (1st round-100 nM, 2nd round- 
50 nM and 3rd round -25 nM). After 3 rounds of panning, enrichment was observed as 
shown in Table 3.2. Monoclonal phage ELISA for 40 clones each from the round 3 
populations was performed.  However, no binders were obtained with phage isolated by 
panning against BPSL1549 or BPSL2748. 13 out of 40 clones screened for BimA showed 
specific binding, with some clones exhibiting more than 10-fold ELISA signal over the 
BSA control (Fig 3.4). Three clones exhibiting the highest ELISA signals (clones C7, D3 
and E8) were shown to bind specifically to antigen in a concentration-dependent manner 
in a sandwich ELISA (Fig 3.5). These clones were sequenced, and each one was found to 








         
 
 












      Figure 3.4:  Monoclonal phage ELISA results for BimA clones isolated from   












6  x 106
BimA
6 x 1081.8 x 107Round 1
1.2  x 1082.1 x 108Round 2







































        Figure 3.5:  Sandwich ELISA for BimA clones C7, D3 and E8 
        Phage antibodies were incubated with serial dilution of BimA protein, and specific 
binding was detected by anti-His antibody. BSA was used as control. 
 






























































  For panning experiments using streptavidin beads, BPSL1549, BPSL2748, BipD 
and BopE were first biotinylated and used at a concentration of 10 µg/ml, 5 µg/ml and 1 
µg/ml for panning rounds 1, 2 and 3 respectively. A significant enrichment was observed 
in all the panning experiments as given in Table 3.3. 30 clones each for BPSL1549, 
BPSL2748, BopE and BipD were screened by monoclonal phage ELISA. Four clones 
that gave ELISA signals at least two-fold above background were obtained for 
BPSL2748, 3 clones for BopE and one for BipD (Fig 3.6, 3.8). We did not find any 
specific binders for BPSL1549. The specificity two clones from BPSL2748 (B5 and B8) 
was tested by sandwich ELISA, and it was found to be antigen concentration dependent, 
(Fig 3.7). Two clones from the BPSL2748 selection, two clones from BopE (E2 and G3) 
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Figure 3.6:  Monoclonal phage ELISA results for BPSL2748 clones isolated from   









Figure 3.7:  Sandwich ELISA for BPSL 2748 clones B5 AND B8 
Phage antibodies were incubated with serial dilution of BPSL 2748 protein, and specific 


































































      Figure 3.8:  Monoclonal phage ELISA for two clones from BopE (E2 & G3) and 





Table 3.4:  CDR sequences of the clones isolated from the library in comparison with the 












Template        FSSSSI     SISSSYGYTY     TVRGSKKPYFSGW~~~~~AM     SSYS~~~LI     
 
2748-B5         LY.YYM     ...PY..S..     SPAWGWHYWGYAPY~~~~..     G..YGY~P.  
2748-B8         LYY.YM     ....Y..S.S     SSFS.WWG.SHWYHPSY~.L     YV.YSS~..  
 
BimA-C7         ......     ..Y..S.S..     AGHYY~~~~~~~~~~~~~G.     ....~~~..  
BimA-D3         IYY.YM     Y.YPY.....     GGYWAYPSAA.~~~~~~~.I     .Y.HPHPP.  
BimA-E8         L.Y.Y.     Y.YP...S..     AYAPY~~~~~~~~~~~~~GL     ..SYAGG..  
  
 
BipD-B3         LYYY.M     ..Y.......     GAYYPGSWSWFWHPSYYW.L     HFAGYWSP.  
 
BopE-E2         ......     ..........     .............~~~~~..     WP.YA~~..  
BopE-G3         ......     ..........     .............~~~~~..     WVPYWA~..  
BopE-H2         I.....     Y..PYSS...     .............~~~~~..     YYSVAWPPF  
CDRH1                 CDRH2                              CDRH3 CDRL3
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DISCUSSION: 
  Monoclonal antibodies have achieved an enormous success as therapeutics in 
recent years for a range of conditions. However, the clinical success has been so far 
elusive for anti-bacterial antibodies, with major limitation being identification of suitable 
antigen targets. The advances in antibody engineering have made it possible to develop 
powerful antibody selection systems and by taking advantage of this technology to 
develop a high-throughput screening system for a wide array of bacterial antigens should 
help overcome the initial hurdles for the development of effective ant-bacterial 
antibodies. 
   Antibodies can play an important role in both diagnosis and therapeutics of 
melioidosis and glanders. Though several antigens have been identified as either 
immunogenic or pathogenic, their role in the pathogenesis of these diseases is not well 
understood. The aim of this study was to set up a high-throughput screening system for 
the selections of antibodies that can be investigated for their functionality in either 
diagnostics or therapeutics.  
   Here we describe the use of a synthetic antibody library, designed by a minimalist 
based approach. In this study, specific depletion steps were included in the phage panning 
steps to eliminate non-specific enrichment of phage. The immobilization of antigens on 
the immunotubes did not yield any binders for BPSL1549 and BPSL2748 indicating that 
these might be weak targets for this approach. However, we could isolate antibodies for 
BPSL2748, by using streptavidin beads approach for panning. The streptavidin beads 
based approach seems more favorable to isolation of antibodies, as we could isolate 
antibodies for 3 different antigens. This emphasizes the importance of considering 
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alternative selection strategies, when a particular selection strategy fails. Overall, the 
selection experiments were successful, in that specific antibodies were obtained for four 
out of five antigens from the potential bio-weapon B. mallei and B. pseudomallei. 
Sequence analysis of the antibodies generated against four antigens reveal highly unique 
CDR sequences. 
 Further characterization of the isolated antibodies will require assessment of their 
specificity and affinity in the soluble antibody format. In addition, further enrichments for 
each antigen will be performed and analyzed; and, if necessary, the library may be 
panned again by including stringent selection steps. Once highly specific antibodies are 
isolated, they will be tested in vitro for their specificity and cross reactivity by either 
using cell lysates or whole cells of B. mallei and B. pseudomallei. 
  This study demonstrates the feasibility of isolating antibodies for a wide-array of 
antigens through the screening of phage-displayed synthetic antibody libraries. 
Furthermore, the antigens used in this study were proved suitable for the selection and 
isolation of antibodies. Future work will focus on selection of antibodies to include 








HIGH-LEVEL PERIPLASMIC EXPRESSION AND PRODUCTION OF AN 
ANTIBODY FRAGMENT (SCAB) AGAINST ANTHRAX TOXIN IN 
Escherichia coli BY HIGH CELL DENSITY FERMENTATION 
INTRODUCTION: 
   Anthrax is an acute infectious disease that is highly lethal in most forms. It is 
caused by a Gram-positive bacteria Bacillus anthracis that forms highly resistant 
endospores under hostile conditions. Following the ingestion or inhalation of these 
spores, bacteria germinate and multiply rapidly within the body. The lethality of the 
anthrax disease is primarily due to the tripartite toxin released by the bacteria, that is 
comprised of a protective antigen (PA), edema factor (EF) and lethal factor (LF). The LF 
and EF exert their toxicity following PA mediated cell entry (185).  
  Anthrax is one of the first biological weapons to be developed, and continues to 
be a major threat. After October 2001 attacks with letters carrying anthrax, there have 
been increased efforts towards developing an effective prophylactic and therapeutic 
treatment, since antibiotic treatment is effective only for a brief period after exposure to 
the spores. Efforts have been focused on developing the anti-toxin antibodies, with PA 
being the major target because of its role in the pathophysiology of anthrax.  
Passive immunization with polyclonal antibodies against PA provides protection 
against challenge with B.anthracis, and antibody titers against PA correlate well with 
protective immunity (102, 108). Our group previously isolated an affinity-matured 
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antibody fragment (M18 scFv) against PA following high-throughput screening of large 
libraries of random mutants (57). To improve the retention of the antibody fragment in 
circulation we conjugated maleimide-PEG to an engineered cysteine residue at the C-
terminus of the M18 scAb.  The PEGylated M18 scAb showed prolonged circulation half 
life and conferred prophylactic protection against heavy challenge with inhalation anthrax 
spores (106). These results were highly significant because antibody fragments do not 
contain the Fc domain of IgG and hence are unable to recruit innate immune cells for the 
killing of the target pathogen. Consequently, protection by the PEGylated antibody 
fragment arises because of its ability to neutralize the toxin without which the bacteria 
cannot survive in vivo. Moreover, it enables the use of antibody fragments for 
therapeutics and presents a prospect of cost-effective production of the antibody 
fragments in bacterial hosts such as Escherichia coli (65, 112). If the use of PEGylated 
antibody fragments were to be employed in the clinic it will be necessary to produce 
large amounts of scAbs.  
   E. coli has proven to be an appropriate host for large scale production because the 
cells can be grown in simple inexpensive media, scale-up is relatively easy due to a short 
fermentation cycle. Large-scale production of recombinant proteins in E. coli has been 
effectively accomplished by high cell density cultivation (HCDC) technologies that can 
achieve cell densities higher than OD600 of 100. A high volumetric productivity is 
achieved by the precise control of the growth medium, culture conditions and nutrient 
feeding strategies.   
  Carter et al., first reported (21) the production of 1~2 g/L of humanized F(ab)2 in 
a 10 L culture. Since then, HCDC of E. coli has been used for the production of many 
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antibody fragments as well as full length IgG. (2, 25, 45, 67, 69, 123, 148, 150, 165).  
Horn et al. (67) performed fed-batch fermentation for the production of dimeric 
miniantibodies against EGF-receptor in a 10 L bioreactor, and successfully obtained more 
than 3 g/L of soluble antibodies, which is the best reported so far.   
Single chain antibodies (scAbs) have a human constant Kappa (HuCk) domain 
connected to the carboxy terminus of a single chain Fv (scFv) and display improved 
stability and enhanced pharmacokinetic properties in comparison to scFv (18, 59, 60, 
112) In spite of its significance, there have been no report of large-scale production of 
recombinant scAbs in E.coli. 
In this chapter, we report the use of HCDC for large-scale production of the M18 
scAb in E. coli.  We examined four different cell densities (OD600 of 40, 80, 120 and 150) 
for induction of protein expression and compared the total production yields of scAb and 
cell growth. We further characterized the solubility and activity of scAb purified from 
HCDC.  
 
MATERIALS AND METHODS: 
Bacterial strains and plasmids: 
    The bacterial strains used in this study are listed in Table A.1.  For cloning 
purposes E. coli Jude 1 [DH10B F':: Tn10 (Tetr)] was used, whereas E. coli XL1-Blue was 
used for HCDC.  The M18 scFv gene was cloned into pMopac16, which expresses a 
fusion of scFv with the human constant κ light chain to create a single chain antibody 
 97 
(scAb) (106). The pMopac16 plasmid (59) has an IPTG inducible lac promoter and 
employs the PelB leader peptide for the secretion of scAb into the periplasm of E. coli. It 
also carries the gene for the skp chaperone for enhanced soluble expression, and a C-
terminal His6 tag with a single Cysteine residue for easy purification and site-specific 
PEGylation, respectively (Fig. A.1A).   
Strains Genotypes Ref 
XL1-Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZ∆M15 Tn10 (Tetr)] 
Stratagene 
Jude1 DH10B F'::Tn10 (Tetr) (52) 
BL21(DE3) F- ompT  hsdSB (rB
- mB
-) gal dcm (DE3) Novagen 
Rosetta2 (DE3) F- ompT hsdSB(rB
- mB
-) gal dcm (DE3) pRARE2 (CamR) Novagen 
HMS174 (DE3) F- recA1 hsdR(rK12
- mK12
+) (DE3) (Rif R) Novagen 
Rosetta gami (DE3) 
F– ompT hsdSB (rB
– mB
–) gal dcm lacY1 ahpC (DE3) gor522::Tn10 
trxB pRARE (CamR, KanR, TetR) 
Novagen 
TG1 Derivative of BL21(DE3), lactose permease (lacY) mutant Lab stock 
DH5α F' Φ80dlacZ ∆M15 ∆(lacZYA-argF)U169 deoR recA1 endA1 
hsdR17(rK
- mK
+) phoA supE44 λ- thi-1 
Lab stock 
DHF′ DH5α F'::Tn10 (Tetr) Lab stock 
Table A 1: List of bacterial strains used in this study. 
 
 Shake flask cultivation: 
    Cells harboring pMoPac16Cys-M18 were cultivated in 125 mL flask containing 
20 ml of Terrific broth (TB - Difco) medium supplemented with 100 µg/ml ampicillin 
(Amp) in a 37°C incubator at 200 rpm. Once the cells reached an OD600 of 0.7, the shake 
flasks were transferred to 25°C for 30 min, and protein expression was induced with 1 
mM IPTG. After cultivation for further 4 hr at 25°C, cells were harvested by 
centrifugation for further expression analysis.   
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High cell density cultivation3: 
    For preparative expression, cells were grown in R/2 medium (77) consisting of 
(NH4)2HPO4, 2 g; KH2PO4, 6.75 g; citric acid, 0.85 g; MgSO47H2O, 0.7 g; trace metal 
solution [per liter of 5 M HCl: FeSO47H2O, 10 g; ZnSO47H2O, 2.25 g; CuSO45H2O, 1 g; 
MnSO45H2O, 0.5 g; Na2B4O710H2O, 0.23 g; CaCl22H2O, 2 g; (NH4)6MO7O24, 0.1 g)] per 
liter with 2% (w/v) glucose.  E.coli XL1 Blue cells harboring pMopac16-cys M18 was 
cultured in 1L flasks containing 150 ml of R/2 media with 2% glucose at 37°C at 250 
rpm for 6 h, and the culture was used to inoculate the fermentor. Fed-Batch fermentations 
were conducted in a 3.5 liter Bioflo 300 fermentor (New Brunswick Scientific Co., 
Edison, NJ) containing 1.5 liter of the same R/2 medium  plus 2% (w/v) glucose with 
10% (v/v) of inoculum (150 mL). The pH was maintained at 6.8 by the addition of 28% 
(v/v) ammonium hydroxide. The dissolved oxygen concentration (DOC) was controlled 
at 40% of air saturation by automatically increasing the agitation speed up to 1,000 rpm 
and then by changing the pure oxygen (O2) percentage.  Two nutrient feeding solutions 
were added into the fermentor by a pH-stat feeding strategy.  Initially, a defined feeding 
nutrient solution (700 g of glucose + 20 g of MgSO4·7H2O per liter) was used in the pre-
induction period.  When the pH rose to a value greater than its set point (6.8) by 0.08 due 
to the depletion of glucose, the appropriate volume of feeding solution was automatically 
added to increase the glucose concentration in the culture broth.  A complex feeding 
solution (500 g of glucose, 100 g of yeast extract and 20 g of MgSO4·7H2O per liter) was 
used in the post-induction period similar to above nutrient feeding strategy.  
                                                 
3 HCDC fermentation was performed by Dr. Ki Jun Jeong 
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 The temperature of the culture in the pre-induction period was maintained at 30°C, and 
was reduced to 25°C for 30 min before inducing with 1 mM IPTG and was maintained at 
25oC during the post-induction period.  Cell growth was monitored by measuring the 
optical density (OD) at 600 nm using an Ultrospec 3000 spectrophotometer (Shimazu, 
Japan).  Culture samples were collected periodically by centrifugation and cell pellets and 
supernatants were stored at -20°C for further analysis.  At the end of fermentation, cells 
were harvested by centrifugation (6,500 rpm, for 20 min at 4oC) and the cell paste was 
stored at -20°C for purification of scAb.  
 
Purification of scAb: 
    For the preparation of the periplasmic fraction by osmotic shock, 2 g of wet cell 
paste from the fermentation culture was resuspended in 10 ml of Tris-sucrose solution 
(100 mM Tris (pH 8.0) + 0.75 M sucrose).  Lysozyme was then added to a final 
concentration of 0.5 mg/ml and incubated on the rotator for 20 min at 4°C.  Following 
incubation, 20 ml of 1 mM EDTA solution was added dropwise, and incubated for 
another 15 min at 4°C.  Finally, 1.5 ml of 0.5 M MgCl2 was added and incubated further 
for 10 minutes.  Spheroplasts were centrifuged at 12,000 rpm, and supernatant 
periplasmic fractions were stored at 4°C for further purification.  To isolate the remaining 
protein from the soluble fraction, the pellet from the osmotic shock procedure was 
homogenized in 20 ml of 1x IMAC buffer [100 mM Tris-HCl, 5 M NaCl, 0.2 M 
imidazole, pH 8.0],  and  then passed through French press (FA-078A, Thermo Electron 
Corporation, Waltham, MA) 3 times.  Cell lysates were centrifuged at 13,000 rpm for 15 
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min at 4°C.  The clarified supernatant along with the periplasmic fraction isolated from 
the osmotic shock procedure was further processed for purification of scAb.   
  Both the periplasmic fraction and soluble fraction from the previous procedure 
were combined with 1/10 volume of 10x IMAC buffer (100 mM Tris-HCl, 5 M NaCl, 0.2 
M imidazole, pH 8.0) and incubated with 2 ml Ni-NTA resin (QIAGEN, Madison, WI) 
for 1 hour with shaking at 4°C.  After washing the resin with 20 ml of 1x IMAC buffer, 
protein was eluted with 500 mM imidazole in 1x IMAC buffer.  The purified M18 scAb 
was then applied to a Superdex 200 HR 10/30 column (Amersham Biosciences, 
Piscataway, NJ) on an Akta Fast-protein liquid chromatography (FPLC) system 
(Amersham Pharmacia, Piscataway, NJ).  ScAb containing fractions were collected and 
quantified using a bicinchoninic acid (BCA) quantification kit (Pierce, Rockford, IL). 
Analysis by SDS-PAGE: 
    For analysis of the production yield and solubility of the expressed scAb, protein 
samples were analyzed by electrophoresis on a pre-cast 4-20% SDS-PAGE (NuSep, 
Lawrenceville, GA) gel followed by western blotting. Bands on the western blots were 
detected by anti-His-HRP conjugated probes with 1:5000 dilutions (Sigma-Aldrich, St. 
Louis, MO). The band intensities on X-ray film were quantified by Quantity One gel 
analysis software (Bio-Rad Hercules, CA) with the purified M18 scAb as a standard.   
ELISAs: 
   50 µl of PA83 (List Biological Laboratories) at 1 µg/ml in PBS was used to coat 
96 well NUNC maxisorp plates (NUNC, Rochester, NY) overnight at 4°C. BSA at 10 
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µg/ml was used as a negative control. Wells were blocked with 2% (w/v) milk in PBS for 
3 hours at room temp. After washing the wells with PBS, 50 µl of purified M18 scAb 
with starting concentration of 5 µg/ml was added to the wells in 1: 3 serial dilutions. The 
plate was placed at room temperature for 2 hours.  After washing the wells 3x with PBST 
(PBS containing 0.05% Tween-20) and once with PBS,  50 µl of goat anti-human Kappa 
light chain HRP (Sigma-Aldrich) at 1:2500 dilutions were added to the wells and 
incubated at room temperature for 1 hour. Following washing, 50 µl of o-
phenylenediamine substrate (Sigma-Aldrich) was added. The plate was kept for 20-30 
min for the color to develop. The reaction was stopped by adding 50 µl of 4.5 N H2SO4 




 Selection of host strain for ScAb expression: 
 
  The genotypes of different E.coli host strains can have a great impact on protein 
expression levels, even under the same expression plasmid and identical culture 
conditions (27, 76). Therefore, choosing a suitable host strain for a high-level production 
of recombinant proteins in HCDC is important. In order to select the best host strain for 
high-level production of scAbs, we evaluated nine different E. coli strains that are 
preferred for recombinant protein production (Table A.1) in shake flask experiments. 
Cells were transformed with pMoPac16Cys-M18, grown under identical conditions in TB 
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medium and the final yield of M18 scAb after 4 hour induction was analyzed by Western 
blotting. While no significant difference in growth rates were observed, the level of scAb 
production varied greatly. E. coli XL1-Blue, DH5α and DHF′ strains showed higher 
expression levels (Fig. A.1B). We chose the E. coli XL1-Blue strain, since it has been 











Figure A.1: Expression of M18 scAb in E. coli. (A) Schematic diagram of plasmid 
pMoPac16Cys_M18 and simple structure of scAb. HuCk region is connected to C-
terminus of VH region, and His hexamer (His6) and single Cys residue were fused to Ck 
region for purification and PEGylation, respectively.  
(B) Analysis of M18 scAb production from shake flask cultivations of nine E. coli 
strains. Lane 1, Jude1; lane 2, XL1-Blue; lane 3, BL21(DE3); lane 4, TG1; lane 5, DH5α; 
lane 6, Rosetta2(DE3); lane 7, Rosetta gami(DE3); lane 8, DHF’; lane 9, HMS174. 
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High Cell Density Cultivation with different induction times: 
   pH-stat fed-batch cultures of E. coli XL1-Blue harboring pMoPac16Cys-M18 
were carried out as described in Materials and Methods. To examine the effect of 
induction time on scAb production, cells were induced with 1 mM IPTG at four different 
cell densities: OD600  40, 80, 120 and 150.  During the fermentation, the temperature was 
maintained at 30oC in the pre induction period and a defined feeding solution (700 g/L of 
glucose plus 20 g/L of MgSO4) was supplied in response to changes in the pH. In the 
post-induction period, the temperature was  decreased to 25oC to allow correct folding of 
the scAb protein in the periplasm, and a yeast extract (100 g/L) mixed feeding solution 
was supplied for enhancing scAb production and cell growth.  Figure A.2 shows the time 
profiles of cell density (OD600) and antibody production yield (mg/L/OD), and data 
including production yields and cell growth for all runs are summarized in Table A.2.   
  Following low cell density (OD600 of 40) induction, cells exhibited a good growth 
rate (µ=0.122 h-1) and reached an OD600 of 110, 10 hrs after induction. Production of 
scAb was observed immediately after induction and increased for up to 8 hrs (Fig. A.2A). 
The volumetric yield reached 665 mg per liter at that time point.  With the induction at an 
intermediate cell density (OD600 of 80), the cells grew to OD600 of 134 in 7 hrs after 
induction and the final yield was 549 mg per liter (Fig. A.2B). When cells were induced 
at high cell densities (OD600 of 120), they exhibited a considerable reduction in growth 
rate (µ = 0.042 h-1) after induction in comparison to that of pre-induction (µ = 0.168 h-1). 
In this case cell density declined after reaching OD600 of 165 at 6 hr after induction (Fig. 
A.2C), and the production yield was only 378 mg per liter.  Induction at another high cell 
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density (OD600 of 150) also showed similar poor cell growth after induction (µ = 0.038 h
-
1) and lower protein production (Fig. A.2D). Interestingly, in all fermentations, scAb 
protein was not detected in the culture medium during the fermentation (data not shown) 
which means neither cell lysis nor permeability increases of the outer membrane occurred 
during HCDC. Even though we used a lac promoter, which is known for its leaky 
expression, (67), we could not find any detectable scAbs during the pre-induction period 
for any of the fermentations (data not shown).  
In two cultures (induction at OD600 of 40 and 120), the solubility of M18 scAb 
produced was compared with end-point samples from both culture.  After cell disruption 
by French press followed by quick centrifugation, the soluble fractions were applied to 
ELISA to evaluate the amount of active scAb. We found that induction at OD600 of 120, 
resulted in a greater amount of soluble and active antibody fragments (77% of total scAb) 
compared to that (51% of total scAb) at low cell density (OD600 of 40). 
 



















(mg/ L/ OD) 
40 111 0.165 0.122 665 6.1 
80 134 0.146 0.081 549 4.1 
120 165 0.168 0.042 378 2.3 
150 186 0.148 0.033 374 2.0 





Figure A.2: Time profiles for cell density () and cell specific production yield 
(mg/L/OD) of M18 scAb () during HCDC with induction at four different cell 
densities: (A) OD600 of 40; (B) OD600 of 80; (C) OD600 of 120; (D) OD600 of 150.  The 







Purification and activity assay:  
   Cells were collected by centrifugation and soluble and periplasmic scAb was 
purified as described in Materials and Methods section. ScAbs are monomeric proteins 
but within the periplasm or during purification, a fraction spontaneously dimerizes, 
resulting in a mixture of monomeric and dimeric fragments (50). The content of 
monomeric scAb in eluates from Ni-NTA column was about 60%, and could be 
successfully separated by size exclusion column chromatography (Fig A.3). The activity 
of the purified scAb was analyzed by ELISA. The ELISA results verified that scAb 
production via HCDC did not affect the activity of the scAb, and purified scAb is 
biologically functional (Fig A.4).    
                        
Figure A.3: SDS-PAGE analysis of samples from each purification step. Lane M, 
molecular mass standards; lane 1, whole cell lysate; lane 2, soluble protein fraction after 
spheroplast cell disruption; lane 3, periplasmic protein fraction by osmotic shock method; 
lane 4, eluate from Ni-NTA column ; lane 5, monomeric scAb fraction after size 




Figure A.4:  Analysis of solubility and activity of M18 scAb purified from HCDC.  
M18 scAb was purified from HCDC cultures and its binding activity to antigen (anthrax 
toxin PA) was analyzed by ELISA.  Bovine serum albumin (BSA) was used as a negative 
control in ELISA.  
 
DISCUSSION: 
    HCDC techniques have been widely used for large-scale production of 
recombinant proteins including antibody fragments in E. coli (96, 146).  Several factors 
are important for cost-effective HCDC including the composition of the growth media, 
the nutrient feeding strategy, oxygen transfer, temperature, and induction (inducer 
concentration, induction time). The culture temperature is an important factor for proper 
folding of scAbs as well as other antibody fragments, and generally low temperatures (30 
or 25oC) are recommended even though E. coli cells grow better at 37oC.  In all the 
fermentations carried out in this study, the temperature was set at 25oC after induction 
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based on studies with shake flask cultures (data not shown).  In fed batch fermentation, 
cell growth and protein production can also be greatly affected by the feeding solution. 
However, the optimization of the nutrient feeding strategy in the pre and post induction 
periods can be labor-intensive and time consuming (177).  In this study, as an alternative, 
we employed a pH-stat feeding strategy, which may not be optimal, but generally results 
in good protein production and cell growth.   
The protein yield is affected by the time of induction (38, 77, 184).  In our study, 
we examined four different cell densities for induction and observed that with an increase 
in cell density at the induction time point, both volumetric and cell specific production 
yields decreased inversely (Table A.2).  Induction at the lowest cell density (OD600 of 40) 
resulted in the best volumetric and cell specific production yield of M18 scAb, yielding 
as high as 665 mg/L of total scAb and 6.1 mg/L/OD respectively, which corresponds to 
approx. 3.5% of total  cell protein.  Even though the soluble fraction of M18 scAb (51% 
of total) was lower compared to that observed in fermentations with induction at OD600 
120 (77%), the total yield of soluble and active scAb in the former case (337 mg/L) was 
higher than that of the latter(291 mg/L).  Induction at OD600 of 40 also showed a much 
better cell growth rate in the post-induction period compared to other conditions.  In the 
pre-induction period, all cultures showed similar growth rates (µ = 0.146 ~ 0.168 h-1), 
however, in the post-induction period, induction at higher cell densities (OD600 of 120 
and 150) showed a dramatic decrease in the cell growth rate (75% ~ 78% compared to 
those of before induction), while induction at OD600 40, resulted in a slower decline (~ 
26%).   In conclusion, when induction was done at low cell density (early growth phase), 
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cells were more viable and environments were more favorable to growth and antibody 
production, and as a result higher amounts of scAbs could be obtained.  
The overproduction of antibody fragments such as scFv or Fabs have in some 
cases resulted in release of the antibodies into the culture by cell lysis. This leads to a 
decrease in cell densities and therefore, reduced final production yields (45, 150, 151).    
In the present study, we could not find any detectable protein in the culture supernatant 
samples by Western blotting.  
 In summary, HCDC of recombinant M18scAb in E. coli was demonstrated to 
enable large scale production. To the best of our knowledge, this is the first report for 
large-scale production of scAbs in E. coli.  Interestingly, highest level production of the 
M18scAb was achieved by induction at low cell density. In addition, more than 1 g of 
scAb could be obtained in one fed-batch cultivation of a 1.8 L culture.  The information 
obtained in this study should be useful for the development of HCDC strategies for the 
efficient production of other antibody fragments including scAbs, as well as other 
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